<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="pmc-domain-id">1559</journal-id><journal-id journal-id-type="pmc-domain">viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC6357101</article-id><article-id pub-id-type="pmcid-ver">PMC6357101.1</article-id><article-id pub-id-type="pmcaid">6357101</article-id><article-id pub-id-type="pmcaiid">6357101</article-id><article-id pub-id-type="pmid">30646569</article-id><article-id pub-id-type="doi">10.3390/v11010060</article-id><article-id pub-id-type="publisher-id">viruses-11-00060</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Zhou</surname><given-names initials="Y">Yusen</given-names></name><xref ref-type="aff" rid="af1-viruses-11-00060">1</xref><xref ref-type="aff" rid="af2-viruses-11-00060">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="Y">Yang</given-names></name><xref ref-type="aff" rid="af3-viruses-11-00060">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="J">Jingwei</given-names></name><xref ref-type="aff" rid="af4-viruses-11-00060">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jiang</surname><given-names initials="S">Shibo</given-names></name><xref ref-type="aff" rid="af4-viruses-11-00060">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Du</surname><given-names initials="L">Lanying</given-names></name><xref ref-type="aff" rid="af4-viruses-11-00060">4</xref><xref rid="c1-viruses-11-00060" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-viruses-11-00060"><label>1</label>State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China; <email>yszhou@bmi.ac.cn</email></aff><aff id="af2-viruses-11-00060"><label>2</label>Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450052, China</aff><aff id="af3-viruses-11-00060"><label>3</label>Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT 06520, USA; <email>y.yang@yale.edu</email></aff><aff id="af4-viruses-11-00060"><label>4</label>Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA; <email>JHuang2@nybc.org</email> (J.H.); <email>SJiang@nybc.org</email> (S.J.)</aff><author-notes><corresp id="c1-viruses-11-00060"><label>*</label>Correspondence: <email>ldu@nybc.org</email>; Tel.: +1-212-570-3459</corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>1</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2019</year></pub-date><volume>11</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">328758</issue-id><elocation-id>60</elocation-id><history><date date-type="received"><day>15</day><month>12</month><year>2018</year></date><date date-type="accepted"><day>10</day><month>1</month><year>2019</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2019</year></date></event><event event-type="pmc-live"><date><day>05</day><month>02</month><year>2019</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2020-04-30 00:36:46.420"><day>30</day><month>04</month><year>2020</year></date></event></pub-history><permissions><copyright-statement>&#169; 2019 by the authors.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access"><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="viruses-11-00060.pdf"/><abstract><p>Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) is an infectious virus that was first reported in 2012. The MERS-CoV genome encodes four major structural proteins, among which the spike (S) protein has a key role in viral infection and pathogenesis. The receptor-binding domain (RBD) of the S protein contains a critical neutralizing domain and is an important target for development of MERS vaccines and therapeutics. In this review, we describe the relevant features of the MERS-CoV S-protein RBD, summarize recent advances in the development of MERS-CoV RBD-based vaccines and therapeutic antibodies, and illustrate potential challenges and strategies to further improve their efficacy.</p></abstract><kwd-group><kwd>Coronavirus</kwd><kwd>MERS-CoV</kwd><kwd>spike protein</kwd><kwd>receptor-binding domain</kwd><kwd>vaccines</kwd><kwd>therapeutics</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1-viruses-11-00060"><title>1. Introduction</title><p>Middle East respiratory syndrome (MERS) coronavirus (CoV) is an infectious virus that was first reported in June 2012 [<xref rid="B1-viruses-11-00060" ref-type="bibr">1</xref>]. MERS-CoV may infect people of any age, but older age, underlying comorbidity (such as diabetes mellitus, renal disease, respiratory disease, heart disease, and hypertension), and delayed confirmation or late diagnosis are all factors that affect MERS disease outcomes and mortality [<xref rid="B2-viruses-11-00060" ref-type="bibr">2</xref>,<xref rid="B3-viruses-11-00060" ref-type="bibr">3</xref>,<xref rid="B4-viruses-11-00060" ref-type="bibr">4</xref>,<xref rid="B5-viruses-11-00060" ref-type="bibr">5</xref>,<xref rid="B6-viruses-11-00060" ref-type="bibr">6</xref>,<xref rid="B7-viruses-11-00060" ref-type="bibr">7</xref>]. Sex could be a factor in MERS epidemiology, as more males seem to be affected than females [<xref rid="B8-viruses-11-00060" ref-type="bibr">8</xref>,<xref rid="B9-viruses-11-00060" ref-type="bibr">9</xref>,<xref rid="B10-viruses-11-00060" ref-type="bibr">10</xref>]. MERS-CoV infection of women during pregnancy has adverse outcomes, with fetal mortality of ~27%; however, only a limited number of pediatric MERS-CoV infections occur [<xref rid="B11-viruses-11-00060" ref-type="bibr">11</xref>,<xref rid="B12-viruses-11-00060" ref-type="bibr">12</xref>,<xref rid="B13-viruses-11-00060" ref-type="bibr">13</xref>,<xref rid="B14-viruses-11-00060" ref-type="bibr">14</xref>]. At the end of December 2018, 2,279 laboratory-confirmed MERS infections were reported globally (in 27 countries), leading to 806 deaths, and a mortality of 35.3%. Among these infections, 1,901 (83.4%) were reported in Saudi Arabia, with mortality in 732 individuals (38.5%) (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.emro.who.int/health-topics/mers-cov/mers-outbreaks.html">http://www.emro.who.int/health-topics/mers-cov/mers-outbreaks.html</uri>). The largest MERS outbreak outside Saudi Arabia occurred in South Korea in 2015, with 186 cases and 38 deaths [<xref rid="B9-viruses-11-00060" ref-type="bibr">9</xref>,<xref rid="B15-viruses-11-00060" ref-type="bibr">15</xref>,<xref rid="B16-viruses-11-00060" ref-type="bibr">16</xref>]. The most recent MERS cases were reported in 2018 in South Korea, the United Kingdom, and Malaysia, in addition to Saudi Arabia, the United Arab Emirates, and Oman (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.who.int/emergencies/mers-cov/en/">http://www.who.int/emergencies/mers-cov/en/</uri>).</p><p>MERS-CoV is thought to have originated in bats [<xref rid="B17-viruses-11-00060" ref-type="bibr">17</xref>,<xref rid="B18-viruses-11-00060" ref-type="bibr">18</xref>,<xref rid="B19-viruses-11-00060" ref-type="bibr">19</xref>,<xref rid="B20-viruses-11-00060" ref-type="bibr">20</xref>]. MERS-like viruses have been isolated from bats that use (at lower efficiency) the same receptor for cell entry as the MERS-CoV isolated from humans [<xref rid="B21-viruses-11-00060" ref-type="bibr">21</xref>,<xref rid="B22-viruses-11-00060" ref-type="bibr">22</xref>,<xref rid="B23-viruses-11-00060" ref-type="bibr">23</xref>]. Dromedary camels are potential intermediates for long-term evolution of MERS-CoV and seasonal zoonotic transfer of virus to humans [<xref rid="B24-viruses-11-00060" ref-type="bibr">24</xref>,<xref rid="B25-viruses-11-00060" ref-type="bibr">25</xref>,<xref rid="B26-viruses-11-00060" ref-type="bibr">26</xref>,<xref rid="B27-viruses-11-00060" ref-type="bibr">27</xref>]. Antibodies specific to MERS-CoV, particularly neutralizing antibodies that neutralize MERS-CoV infection, have been detected in the sera of dromedary camels from a number of countries and regions, with high positive detection rates [<xref rid="B28-viruses-11-00060" ref-type="bibr">28</xref>,<xref rid="B29-viruses-11-00060" ref-type="bibr">29</xref>,<xref rid="B30-viruses-11-00060" ref-type="bibr">30</xref>,<xref rid="B31-viruses-11-00060" ref-type="bibr">31</xref>,<xref rid="B32-viruses-11-00060" ref-type="bibr">32</xref>,<xref rid="B33-viruses-11-00060" ref-type="bibr">33</xref>,<xref rid="B34-viruses-11-00060" ref-type="bibr">34</xref>]. In addition to camel-to-camel transmission of MERS-CoV, camel-to-human transmission can occur via direct or indirect contact with sick animals [<xref rid="B35-viruses-11-00060" ref-type="bibr">35</xref>]. There is a high prevalence of MERS-CoV infection in camel workers, particularly in Saudi Arabia [<xref rid="B27-viruses-11-00060" ref-type="bibr">27</xref>]. Following infection of individuals, human-to-human transmission of MERS-CoV occurs frequently, and mainly contributes to community or healthcare-associated outbreaks [<xref rid="B36-viruses-11-00060" ref-type="bibr">36</xref>,<xref rid="B37-viruses-11-00060" ref-type="bibr">37</xref>,<xref rid="B38-viruses-11-00060" ref-type="bibr">38</xref>,<xref rid="B39-viruses-11-00060" ref-type="bibr">39</xref>,<xref rid="B40-viruses-11-00060" ref-type="bibr">40</xref>,<xref rid="B41-viruses-11-00060" ref-type="bibr">41</xref>,<xref rid="B42-viruses-11-00060" ref-type="bibr">42</xref>,<xref rid="B43-viruses-11-00060" ref-type="bibr">43</xref>,<xref rid="B44-viruses-11-00060" ref-type="bibr">44</xref>,<xref rid="B45-viruses-11-00060" ref-type="bibr">45</xref>]. Infection of humans by MERS-CoV, which mainly occurs through the lower respiratory tract, causes severe respiratory symptoms, leading to failure of the respiratory system and/or other organs [<xref rid="B7-viruses-11-00060" ref-type="bibr">7</xref>,<xref rid="B46-viruses-11-00060" ref-type="bibr">46</xref>,<xref rid="B47-viruses-11-00060" ref-type="bibr">47</xref>]. On rare occasions, the human intestinal tract can be an alternative infection route [<xref rid="B46-viruses-11-00060" ref-type="bibr">46</xref>,<xref rid="B48-viruses-11-00060" ref-type="bibr">48</xref>].</p><p>Anti-MERS-CoV antibodies, including neutralizing antibodies, are found in infected patients, some of whom have persistently presented such antibodies for up to 34 months after the disease outbreak [<xref rid="B49-viruses-11-00060" ref-type="bibr">49</xref>,<xref rid="B50-viruses-11-00060" ref-type="bibr">50</xref>]. Antibody responses, and particularly neutralizing antibody responses, are crucial factors in the successful treatment of MERS-CoV infections in humans [<xref rid="B50-viruses-11-00060" ref-type="bibr">50</xref>,<xref rid="B51-viruses-11-00060" ref-type="bibr">51</xref>,<xref rid="B52-viruses-11-00060" ref-type="bibr">52</xref>]. In this regard, the plasma of convalescent MERS-CoV-infected patients is useful for treatment of MERS-CoV infection clinically, but it requires a neutralizing antibody titer (e.g., 50% plaque-reduction neutralization titer: PRNT<sub>50</sub>) &#8805;1:80 to obtain effective therapeutic results [<xref rid="B51-viruses-11-00060" ref-type="bibr">51</xref>,<xref rid="B52-viruses-11-00060" ref-type="bibr">52</xref>,<xref rid="B53-viruses-11-00060" ref-type="bibr">53</xref>]. Currently, a human polyclonal IgG antibody (SAB-301) that is produced by transchromosomic cattle immunized with a MERS-CoV vaccine [<xref rid="B54-viruses-11-00060" ref-type="bibr">54</xref>], as well as several vaccine candidates (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03399578">https://clinicaltrials.gov/ct2/show/NCT03399578</uri>; <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03615911">https://clinicaltrials.gov/ct2/show/NCT03615911</uri>) [<xref rid="B55-viruses-11-00060" ref-type="bibr">55</xref>], have been tested in human clinical trials. However, as yet no vaccines or therapeutic agents have been approved for the prevention or treatment of MERS, indicating the need for further development of novel and effective vaccines and therapeutics against MERS-CoV infection.</p><p>In the following review, we will briefly describe MERS-CoV spike (S) protein receptor-binding domain (RBD), and summarize recent advances in the development of RBD-based MERS-CoV vaccines and therapeutics, as well as the potential challenges and future expectations for their successful development.</p></sec><sec id="sec2-viruses-11-00060"><title>2. MERS-CoV S Protein RBD</title><p>MERS-CoV belongs to the genus <italic toggle="yes">Betacoronavirus</italic>, as does the severe acute respiratory syndrome (SARS)-CoV [<xref rid="B56-viruses-11-00060" ref-type="bibr">56</xref>,<xref rid="B57-viruses-11-00060" ref-type="bibr">57</xref>]. MERS-CoV is a positive-sense, single-stranded RNA virus with a genome that encodes the structural proteins S, envelope (E), membrane (M), and nucleocapsid (N), as well as non-structural proteins (nsp1&#8211;16) translated from open reading frames (ORFs) 1a and 1b, and several accessory proteins, such as 3, 4a, 4b, 5, and 8b (<xref ref-type="fig" rid="viruses-11-00060-f001">Figure 1</xref>A,B) [<xref rid="B58-viruses-11-00060" ref-type="bibr">58</xref>,<xref rid="B59-viruses-11-00060" ref-type="bibr">59</xref>,<xref rid="B60-viruses-11-00060" ref-type="bibr">60</xref>,<xref rid="B61-viruses-11-00060" ref-type="bibr">61</xref>]. The functions of these proteins have been elucidated. As an example, nsp1 is known to have an endonucleolytic RNA-cleavage function in the promotion of infectious virus particle production in human cells [<xref rid="B62-viruses-11-00060" ref-type="bibr">62</xref>], and it also participates in efficient viral replication through interaction with viral RNA, probably via a cis-acting element at the 5&#8242;-terminal coding region [<xref rid="B63-viruses-11-00060" ref-type="bibr">63</xref>]. Evidence indicates that nsp16 is necessary for interferon resistance and viral pathogenesis [<xref rid="B64-viruses-11-00060" ref-type="bibr">64</xref>], whereas nsp15 is a nidoviral uridylate-specific endoribonuclease, the structure of which has recently been resolved, and its activity may be mediated by catalytic residues, oligomeric assembly, or RNA-binding efficiency [<xref rid="B65-viruses-11-00060" ref-type="bibr">65</xref>]. In addition, 4a protein recognizes and binds double-stranded (ds)RNA, in which four residues of the protein might be crucial for 4a-dsRNA stability [<xref rid="B66-viruses-11-00060" ref-type="bibr">66</xref>], and it also inhibits protein kinase R-mediated antiviral stress responses [<xref rid="B67-viruses-11-00060" ref-type="bibr">67</xref>]. 4a mediated-inhibition of stress-granule formation may facilitate viral translation, resulting in efficient MERS-CoV replication [<xref rid="B68-viruses-11-00060" ref-type="bibr">68</xref>]. The MERS-CoV 4b protein interferes with the NF-<italic toggle="yes">&#954;</italic>B-dependent innate immune response during infection [<xref rid="B69-viruses-11-00060" ref-type="bibr">69</xref>].</p><p>MERS-CoV S protein has an important role in viral pathogenesis, determining host tropism and entry into host cells [<xref rid="B58-viruses-11-00060" ref-type="bibr">58</xref>,<xref rid="B70-viruses-11-00060" ref-type="bibr">70</xref>,<xref rid="B71-viruses-11-00060" ref-type="bibr">71</xref>]. The S protein contains an S1 subunit at the N terminus and an S2 subunit at the C terminus. The S1 subunit is composed of the N-terminal domain (NTD) and RBD [<xref rid="B58-viruses-11-00060" ref-type="bibr">58</xref>,<xref rid="B72-viruses-11-00060" ref-type="bibr">72</xref>,<xref rid="B73-viruses-11-00060" ref-type="bibr">73</xref>]. The RBD has a key role in the mediation of binding of MERS-CoV to cells expressing dipeptidyl peptidase 4 (DPP4) receptor, enabling the virus to enter into target cells by fusing with cell membranes through the formation of a fusion core (<xref ref-type="fig" rid="viruses-11-00060-f001">Figure 1</xref>C) [<xref rid="B74-viruses-11-00060" ref-type="bibr">74</xref>,<xref rid="B75-viruses-11-00060" ref-type="bibr">75</xref>,<xref rid="B76-viruses-11-00060" ref-type="bibr">76</xref>,<xref rid="B77-viruses-11-00060" ref-type="bibr">77</xref>]. The S protein requires host cellular proteases for its activity in viral entry, but although evidence initially indicated that cellular furin activates S protein, subsequent results have demonstrated no evidence for the involvement of furin during viral entry [<xref rid="B71-viruses-11-00060" ref-type="bibr">71</xref>,<xref rid="B78-viruses-11-00060" ref-type="bibr">78</xref>]. The DPP4 receptor varies among different host species, and MERS-CoV is thought to use multiple pathways to enable rapid adaptation to species-specific variations [<xref rid="B79-viruses-11-00060" ref-type="bibr">79</xref>,<xref rid="B80-viruses-11-00060" ref-type="bibr">80</xref>,<xref rid="B81-viruses-11-00060" ref-type="bibr">81</xref>].</p><p>In addition to DPP4, MERS-CoV can bind to sialic acid via the S1 subunit of S protein, or utilize the membrane-associated 78 kDa glucose-regulated protein (GRP78) to attach to target cells, suggesting that these proteins may also have roles in virion attachment [<xref rid="B82-viruses-11-00060" ref-type="bibr">82</xref>,<xref rid="B83-viruses-11-00060" ref-type="bibr">83</xref>].</p><p>The structures of MERS-CoV RBD alone and complexed with DPP4 have been determined (<xref ref-type="fig" rid="viruses-11-00060-f002">Figure 2</xref>) [<xref rid="B77-viruses-11-00060" ref-type="bibr">77</xref>,<xref rid="B84-viruses-11-00060" ref-type="bibr">84</xref>,<xref rid="B85-viruses-11-00060" ref-type="bibr">85</xref>]. The RBD has a fold-rich tertiary structure, which consists of a core and a receptor-binding motif (RBM), with stabilization provided by four disulfide bonds and two glycans [<xref rid="B77-viruses-11-00060" ref-type="bibr">77</xref>]. A number of RBD residues are located at the DPP4-binding interface, and they have a critical role in RBD&#8211;DPP4 binding [<xref rid="B77-viruses-11-00060" ref-type="bibr">77</xref>,<xref rid="B84-viruses-11-00060" ref-type="bibr">84</xref>,<xref rid="B85-viruses-11-00060" ref-type="bibr">85</xref>]. Structural analysis of MERS-CoV trimeric S protein has identified specific features of the RBD and its complex with DPP4. Notably, in the prefusion conformation of the S trimer, individual RBDs are either buried (lying state) or exposed (standing state), and this flexibility presumably facilitates recognition by DPP4 [<xref rid="B86-viruses-11-00060" ref-type="bibr">86</xref>]. Other structural studies have revealed four S-trimer conformational states, in which each RBD is either tightly packed at the membrane-distal apex or rotated into a receptor-accessible conformation, suggesting fusion initiation through sequential RBD events [<xref rid="B87-viruses-11-00060" ref-type="bibr">87</xref>]. In configurations with one, two, or three RBDs rotated out, RBD determinants are exposed at the apex of the RBD&#8211;DPP4 complex, and they are accessible for interaction with DPP4 (<xref ref-type="fig" rid="viruses-11-00060-f003">Figure 3</xref>) [<xref rid="B87-viruses-11-00060" ref-type="bibr">87</xref>].</p><p>The function and structure of the S-protein RBD demonstrate that it is an important target for development of vaccines and therapeutic agents against MERS-CoV.</p></sec><sec id="sec3-viruses-11-00060"><title>3. Recent Advances in the Development of Vaccines Based on the MERS-CoV S-Protein RBD</title><p>A number of MERS vaccines have been developed based on viral RBD, including nanoparticles, virus-like particles (VLPs), and recombinant proteins, and their protective efficacy has been evaluated in animal models, including mice with adenovirus 5 (Ad5)-directed expression of human DPP4 (Ad5/hDPP4), hDPP4-transgenic (hDPP4-Tg) mice, and non-human primates (NHPs) [<xref rid="B88-viruses-11-00060" ref-type="bibr">88</xref>,<xref rid="B89-viruses-11-00060" ref-type="bibr">89</xref>,<xref rid="B90-viruses-11-00060" ref-type="bibr">90</xref>,<xref rid="B91-viruses-11-00060" ref-type="bibr">91</xref>,<xref rid="B92-viruses-11-00060" ref-type="bibr">92</xref>,<xref rid="B93-viruses-11-00060" ref-type="bibr">93</xref>,<xref rid="B94-viruses-11-00060" ref-type="bibr">94</xref>]. Features of these RBD-based vaccines, in terms of functionality, antigenicity, immunogenicity, and protective ability, are shown in <xref rid="viruses-11-00060-t001" ref-type="table">Table 1</xref>. </p><p>A soluble nanoparticle vaccine formed in <italic toggle="yes">Escherichia coli</italic> by the RNA-mediated folding of a RBD-ferritin (FR) hybrid elicits robust RBD-specific antibody and cellular immune responses in mice, producing antisera that effectively block the binding of RBD to hDPP4 in vitro [<xref rid="B89-viruses-11-00060" ref-type="bibr">89</xref>]. The adjuvants alum and the squalene-based MF59 significantly augment the antibody titers and T-cell responses induced by RBD&#8211;FR nanoparticle vaccines engineered with or without a SSG linker [<xref rid="B89-viruses-11-00060" ref-type="bibr">89</xref>]. Similarly, a chimeric, spherical VLP (sVLP) vaccine expressing MERS-CoV RBD induces specific antibody and cellular immune responses in mice, preventing pseudotyped MERS-CoV entry into susceptible cells [<xref rid="B90-viruses-11-00060" ref-type="bibr">90</xref>]. The protective efficacy of these two types of MERS vaccine does not yet seem to have been investigated in a viral-challenge animal model.</p><p>Recombinant vaccines involving RBD subunits have been extensively studied for protection against MERS-CoV infection in MERS-CoV-susceptible animal models [<xref rid="B93-viruses-11-00060" ref-type="bibr">93</xref>,<xref rid="B95-viruses-11-00060" ref-type="bibr">95</xref>,<xref rid="B96-viruses-11-00060" ref-type="bibr">96</xref>,<xref rid="B97-viruses-11-00060" ref-type="bibr">97</xref>,<xref rid="B100-viruses-11-00060" ref-type="bibr">100</xref>,<xref rid="B101-viruses-11-00060" ref-type="bibr">101</xref>]. A recombinant RBD (rRBD) fragment (residues 367&#8211;606) expressed in insect cells elicits an antibody response and the production of neutralizing antibodies in mice and NHPs [<xref rid="B88-viruses-11-00060" ref-type="bibr">88</xref>,<xref rid="B91-viruses-11-00060" ref-type="bibr">91</xref>]. It gives incomplete protection in MERS-CoV-challenged NHPs, with the alleviation of pneumonia and clinical manifestations, as well as the reduction of viral load in lung, trachea, and oropharyngeal swabs [<xref rid="B91-viruses-11-00060" ref-type="bibr">91</xref>].</p><p>A MERS-CoV S-protein RBD fragment containing residues 377&#8211;588 has been identified as a critical neutralizing domain [<xref rid="B95-viruses-11-00060" ref-type="bibr">95</xref>]. A treatment regimen involving two doses of a fusion of this fragment and the Fc region of human IgG (S377-588-Fc) four weeks apart is able to induce strong, long-term antibody responses (including production of neutralizing antibodies) in mice [<xref rid="B98-viruses-11-00060" ref-type="bibr">98</xref>]. These responses are significantly greater than those with a single dose or two doses at intervals of one, two, or three weeks [<xref rid="B98-viruses-11-00060" ref-type="bibr">98</xref>]. rRBDs with single or multiple mutations corresponding to S-protein sequences of MERS-CoV strains isolated from humans or camels from 2012 to 2015 have also been studied [<xref rid="B100-viruses-11-00060" ref-type="bibr">100</xref>]. All these rRBDs bind RBD-specific neutralizing monoclonal antibodies (mAbs) and DPP4, and are highly immunogenic, eliciting the production of S1-specific antibodies in mice, which cross-neutralizes multiple MERS pseudoviruses and live MERS-CoV [<xref rid="B100-viruses-11-00060" ref-type="bibr">100</xref>]. A trimeric RBD-Fd protein formed by fusing a MERS-CoV RBD fragment (residues 377&#8211;588) to the foldon trimerization motif, binds strongly to DPP4, and elicits robust and long-term responses with the production of MERS-CoV S1-specific antibodies and neutralizing antibodies in mice, and protects hDPP4-Tg mice against MERS-CoV infection [<xref rid="B94-viruses-11-00060" ref-type="bibr">94</xref>].</p><p>The protection provided by existing subunit vaccines based on wild-type MERS-CoV RBD is not complete, with survival rates in hDPP4-Tg mice after a MERS-CoV challenge of ~67% for S377-588-Fc and 83% for RBD-Fd [<xref rid="B94-viruses-11-00060" ref-type="bibr">94</xref>,<xref rid="B98-viruses-11-00060" ref-type="bibr">98</xref>]. However, a variant RBD (T579N) vaccine produced by masking a non-neutralizing epitope at residue 579 with a glycan probe has both functionality in binding DPP4, and antigenicity in binding four potent MERS-CoV RBD-specific neutralizing mAbs (hHS-1, m336, m337, and m338) [<xref rid="B93-viruses-11-00060" ref-type="bibr">93</xref>]. The T579N vaccine has significantly greater efficacy than the wild-type RBD vaccine, and it fully protects against a lethal MERS-CoV challenge in immunized hDPP4-Tg mice [<xref rid="B93-viruses-11-00060" ref-type="bibr">93</xref>], demonstrating the possibility of developing RBD-based MERS-CoV vaccines with high efficacy.</p></sec><sec id="sec4-viruses-11-00060"><title>4. Recent Advances in the Development of Therapeutics Based on the MERS-CoV S-Protein RBD</title><p>MERS-CoV RBD-targeting antibodies have been developed as effective tools to prevent and treat MERS-CoV infections [<xref rid="B102-viruses-11-00060" ref-type="bibr">102</xref>,<xref rid="B103-viruses-11-00060" ref-type="bibr">103</xref>,<xref rid="B104-viruses-11-00060" ref-type="bibr">104</xref>,<xref rid="B105-viruses-11-00060" ref-type="bibr">105</xref>,<xref rid="B106-viruses-11-00060" ref-type="bibr">106</xref>,<xref rid="B107-viruses-11-00060" ref-type="bibr">107</xref>,<xref rid="B108-viruses-11-00060" ref-type="bibr">108</xref>,<xref rid="B109-viruses-11-00060" ref-type="bibr">109</xref>]. These antibodies generally have greater neutralizing activity against MERS-CoV infection than non-RBD S1-based or S2-based antibodies [<xref rid="B58-viruses-11-00060" ref-type="bibr">58</xref>,<xref rid="B103-viruses-11-00060" ref-type="bibr">103</xref>,<xref rid="B110-viruses-11-00060" ref-type="bibr">110</xref>,<xref rid="B111-viruses-11-00060" ref-type="bibr">111</xref>]. The prophylactic and therapeutic efficacies of RBD-targeting antibodies have been tested in Ad5/hDPP4 mice, hDPP4-Tg mice, and NHPs [<xref rid="B102-viruses-11-00060" ref-type="bibr">102</xref>,<xref rid="B104-viruses-11-00060" ref-type="bibr">104</xref>,<xref rid="B112-viruses-11-00060" ref-type="bibr">112</xref>,<xref rid="B113-viruses-11-00060" ref-type="bibr">113</xref>,<xref rid="B114-viruses-11-00060" ref-type="bibr">114</xref>].</p><p>In an earlier review, we described the antiviral mechanisms, in vivo protection, and crystal structures of previously reported MERS-CoV RBD-specific mAbs, including mouse mAbs Mersmab1, 2E6, 4C2, F11, and D12, and human mAbs LCA60, MERS-4, MERS-27, REGN3048, REGN3051, 1E9, 1F8, 3A1, 3B11, 3B12, 3B11-N, 3C12, M14D3, m336, m337, m338, hMS-1, and 4C2h [<xref rid="B58-viruses-11-00060" ref-type="bibr">58</xref>]. In this review, we focus on newly reported antibodies targeting MERS-CoV S-protein RBD, or on newly identified features of existing mAbs that were not described previously (<xref rid="viruses-11-00060-t002" ref-type="table">Table 2</xref>) [<xref rid="B102-viruses-11-00060" ref-type="bibr">102</xref>,<xref rid="B112-viruses-11-00060" ref-type="bibr">112</xref>,<xref rid="B113-viruses-11-00060" ref-type="bibr">113</xref>,<xref rid="B114-viruses-11-00060" ref-type="bibr">114</xref>,<xref rid="B115-viruses-11-00060" ref-type="bibr">115</xref>].</p><sec id="sec4dot1-viruses-11-00060"><title>4.1. MERS-CoV S-Protein RBD-Targeting mAbs</title><p>RBD-targeting human mAbs have been extensively reported. Most of these mAbs can neutralize pseudotyped or live MERS-CoV in vitro, and some have shown protection against MERS-CoV infection in animal models in vivo [<xref rid="B102-viruses-11-00060" ref-type="bibr">102</xref>,<xref rid="B112-viruses-11-00060" ref-type="bibr">112</xref>,<xref rid="B113-viruses-11-00060" ref-type="bibr">113</xref>,<xref rid="B114-viruses-11-00060" ref-type="bibr">114</xref>,<xref rid="B115-viruses-11-00060" ref-type="bibr">115</xref>]. The structures of several of these mAbs with their antigen-binding fragments (Fabs) or single-chain variable fragments (scFvs) complexed with RBD are known (<xref ref-type="fig" rid="viruses-11-00060-f004">Figure 4</xref>) [<xref rid="B102-viruses-11-00060" ref-type="bibr">102</xref>,<xref rid="B112-viruses-11-00060" ref-type="bibr">112</xref>,<xref rid="B113-viruses-11-00060" ref-type="bibr">113</xref>,<xref rid="B114-viruses-11-00060" ref-type="bibr">114</xref>,<xref rid="B115-viruses-11-00060" ref-type="bibr">115</xref>]. Binding of these mAbs to RBD involves two major recognition modes, with binding to RBD residues contacted by or overlapping with DPP4 (as is the case for GD-27, MCA1, and CDC2-C2), or with binding to the RBD residues outside of the DPP4-binding interface (as seen with MERS-4) (<xref rid="viruses-11-00060-t002" ref-type="table">Table 2</xref>). </p><p>The human mAbs MERS-GD27 and MERS-GD33 each recognize distinct regions of the RBD [<xref rid="B113-viruses-11-00060" ref-type="bibr">113</xref>]. These mAbs have a synergistic effect in the neutralization of pseudotyped MERS-CoV in vitro, with a much lower half-maximal inhibitory concentration (IC<sub>50</sub>) for their use in combination than separately [<xref rid="B113-viruses-11-00060" ref-type="bibr">113</xref>]. An analysis of crystal structures has indicated that MERS-GD27 binds RBD at the DPP4-binding site, and that the neutralization and recognition epitopes almost completely overlap this site, as seen previously for MERS-CoV RBD-targeting neutralizing mAbs, such as m336 [<xref rid="B106-viruses-11-00060" ref-type="bibr">106</xref>,<xref rid="B113-viruses-11-00060" ref-type="bibr">113</xref>]. The MERS-GD27 mAb protects hDPP4-Tg mice from MERS-CoV challenge, both preventively and therapeutically, with significantly lower lung virus titers and RNA copy numbers at day 5 post-challenge, and higher survival rates (60% for pre-challenge vaccination and 40% for post-challenge vaccination) relative to control mice treated with an irrelevant mAb [<xref rid="B112-viruses-11-00060" ref-type="bibr">112</xref>]. </p><p>The human mAb MCA1 was isolated from a MERS survivor via the construction of a phage-display antibody library from peripheral B cells [<xref rid="B114-viruses-11-00060" ref-type="bibr">114</xref>]. Crystal structure analysis indicates that MCA1 binds MERS-CoV S-protein RBD at residues involved in receptor binding, thus interfering with RBD binding to hDPP4 (<xref ref-type="fig" rid="viruses-11-00060-f004">Figure 4</xref>A) [<xref rid="B114-viruses-11-00060" ref-type="bibr">114</xref>]. This mAb prophylactically and therapeutically inhibits MERS-CoV replication in common marmosets, resulting in significantly improved outcomes and reduced lung disease, compared with unvaccinated controls, and undetectable virus titers 3 days post-challenge [<xref rid="B114-viruses-11-00060" ref-type="bibr">114</xref>].</p><p>A probe-based single-B-cell cloning strategy has been used for the isolation of CDC2-C2 and CDC2-C5 mAbs from a patient convalescing from MERS, as well as for the isolation of JC57-11 and JC57-14 mAbs from NHPs immunized with MERS-CoV full-length S DNA and protein [<xref rid="B102-viruses-11-00060" ref-type="bibr">102</xref>]. All these antibodies have neutralizing activities against both pseudotyped and live MERS-CoV. Among them, CDC2-C2 is the most potent against 10 pseudotyped MERS-CoV strains, with neutralization IC<sub>50</sub> values ranging from 0.002 &#181;g/mL to 0.011 &#181;g/mL [<xref rid="B102-viruses-11-00060" ref-type="bibr">102</xref>]. Crystal-structure analysis of the CDC2-C2 and JC57-14 Fab&#8211;RBD complexes indicates that both mAbs bind RBD in the &#8220;out&#8221; (exposed) position, with the CDC2-C2 RBD binding overlapping with the DPP4-contacting residues (<xref ref-type="fig" rid="viruses-11-00060-f004">Figure 4</xref>B,C) [<xref rid="B102-viruses-11-00060" ref-type="bibr">102</xref>]. In addition, CDC2-C2 prophylactically protects hDPP4-Tg mice from MERS-CoV infection, resulting in no detectable viral replication in the lungs three days post-challenge, and no fatalities over 28 days of observation [<xref rid="B102-viruses-11-00060" ref-type="bibr">102</xref>].</p><p>The human mAb MERS-4 also neutralizes pseudotyped MERS-CoV and, notably, displays synergistic neutralization in combination with the MERS-CoV S-protein RBD-targeting MERS-27 and m336 mAbs [<xref rid="B106-viruses-11-00060" ref-type="bibr">106</xref>,<xref rid="B118-viruses-11-00060" ref-type="bibr">118</xref>], as well as the S-protein NTD-targeting 5F9 mAb, in each case with dramatic reduction of the IC<sub>50</sub> compared with individual mAbs [<xref rid="B115-viruses-11-00060" ref-type="bibr">115</xref>]. Structural analysis of a MERS-4-Fab&#8211;RBD complex revealed that MERS-4 binds the RBD from outside the DPP4-binding interface, rather than competing with DPP4 (<xref ref-type="fig" rid="viruses-11-00060-f004">Figure 4</xref>D). Unlike MERS-27, which binds RBD regardless of its conformational state within the S trimer, MERS-4 binds RBD in the &#8220;standing&#8221; position where its epitopes are readily exposed and accessible [<xref rid="B115-viruses-11-00060" ref-type="bibr">115</xref>]. Thus, MERS-4 displays unique epitope specificity, and an unusual mechanism of action involving indirect interference with DPP4 binding through conformational changes, which may explain the observation of synergistic neutralization in combination with other mAbs [<xref rid="B115-viruses-11-00060" ref-type="bibr">115</xref>].</p></sec><sec id="sec4dot2-viruses-11-00060"><title>4.2. Nanobodies Targeting the MERS-CoV S-protein RBD</title><p>Single-domain antibody fragments (VHHs), or nanobodies, are the antigen-recognition regions of camelid heavy-chain-only antibodies (HcAbs), which do not contain light chains. VHHs are easily expressed with high yield, and they have intrinsic stability, strong binding affinity, and specificity to target antigens, and they have therefore been developed as important therapeutic tools against viral infection, including that of MERS-CoV [<xref rid="B116-viruses-11-00060" ref-type="bibr">116</xref>,<xref rid="B117-viruses-11-00060" ref-type="bibr">117</xref>,<xref rid="B119-viruses-11-00060" ref-type="bibr">119</xref>,<xref rid="B120-viruses-11-00060" ref-type="bibr">120</xref>,<xref rid="B121-viruses-11-00060" ref-type="bibr">121</xref>,<xref rid="B122-viruses-11-00060" ref-type="bibr">122</xref>,<xref rid="B123-viruses-11-00060" ref-type="bibr">123</xref>].</p><p>Four VHHs (VHH-1, VHH-4, VHH-83, and VHH-101) have been identified from bone marrow cells of dromedary camels immunized with modified vaccinia virus (MVA) expressing MERS-CoV S protein, and challenged with MERS-CoV [<xref rid="B116-viruses-11-00060" ref-type="bibr">116</xref>]. These VHHs bind MERS-CoV S protein with low <italic toggle="yes">K</italic><sub>d</sub> values (0.1&#8211;1 nM), recognize an epitope at residue D539 of RBD, and neutralize MERS-CoV (PRNT<sub>50</sub>, 0.0014&#8211;0.012 &#181;g/mL) [<xref rid="B116-viruses-11-00060" ref-type="bibr">116</xref>]. These four monomeric VHHs have each been fused with a C-terminal human IgG2 tag to generate four HCAbs (HCAb-1, HCAb-4, HCAb-83, and HCAb-101), with a higher binding affinity and a longer half-life than the free VHHs [<xref rid="B116-viruses-11-00060" ref-type="bibr">116</xref>]. Studies of protective efficacy show that hDPP4-Tg mice (K18) injected with monomeric VHH-83 (20 or 200 &#181;g per mouse) lose weight, and die within seven days post-infection, possibly because of the short half-life of the VHH. However, when the mice are injected with HCAb-83 (200 &#181;g per mouse), which has an extended half-life (~4.5 days), protection against MERS-CoV is complete, with no viral titers or pathological changes in the lungs of virally challenged mice [<xref rid="B116-viruses-11-00060" ref-type="bibr">116</xref>].</p><p>By immunizing llamas with a recombinant RBD fragment (residues 377&#8211;588) fused to a C-terminal human IgG Fc tag (S377-588-Fc), we constructed a VHH library, and we used it to generate a monomeric VHH, NbMS10, and a human Fc-fused VHH, NbMS10-Fc [<xref rid="B117-viruses-11-00060" ref-type="bibr">117</xref>]. Both VHHs can be expressed in a yeast expression system to high purity, and bind RBD with high affinity, recognizing a conformational epitope (residue 539) at the RBD&#8211;DPP4 interface, and blocking the binding of RBD to DPP4. These VHHs, particularly NbMS10-Fc, potently cross-neutralize pseudotyped MERS-CoV strains isolated from different countries, hosts, and time periods [<xref rid="B117-viruses-11-00060" ref-type="bibr">117</xref>]. Importantly, the Fc-fused NbMS10-Fc significantly improves the serum half-life of NbMS10, and a single-dose treatment of hDPP4-Tg mice with this agent completely protects them against lethal MERS-CoV challenge [<xref rid="B117-viruses-11-00060" ref-type="bibr">117</xref>]. These single-domain VHHs demonstrate the feasibility of developing cost-effective, potent, and broad-spectrum therapeutic antibodies against MERS-CoV infection.</p></sec></sec><sec id="sec5-viruses-11-00060"><title>5. Potential Challenges and Future Perspectives</title><p>Compared with vaccines based on MERS-CoV full-length S protein, which have the potential to attenuate neutralizing activity or enhance immune pathology, vaccines developed from MERS-CoV S-protein RBD are safer, and they do not cause immunological toxicity or eosinophilic immune enhancement [<xref rid="B55-viruses-11-00060" ref-type="bibr">55</xref>,<xref rid="B99-viruses-11-00060" ref-type="bibr">99</xref>,<xref rid="B110-viruses-11-00060" ref-type="bibr">110</xref>,<xref rid="B124-viruses-11-00060" ref-type="bibr">124</xref>]. Moreover, RBD-based therapeutic antibodies are generally more potent than non-RBD S1-based or S2-based antibodies [<xref rid="B58-viruses-11-00060" ref-type="bibr">58</xref>,<xref rid="B104-viruses-11-00060" ref-type="bibr">104</xref>,<xref rid="B111-viruses-11-00060" ref-type="bibr">111</xref>]. Hence, RBD-based vaccines and therapeutic antibodies have the potential for further development as effective tools to prevent and treat MERS-CoV infection.</p><p>Despite their acknowledged advantages, there are some issues associated with RBD-based interventions that need to be addressed. For example, RBD is under a high level of pressure of positive selection, and mutations occur in the RBD-DPP4 binding interface that might reduce the efficacy of these treatments [<xref rid="B100-viruses-11-00060" ref-type="bibr">100</xref>,<xref rid="B125-viruses-11-00060" ref-type="bibr">125</xref>,<xref rid="B126-viruses-11-00060" ref-type="bibr">126</xref>,<xref rid="B127-viruses-11-00060" ref-type="bibr">127</xref>]. One possible way to avoid this effect, and to delay the emergence of escape mutants is to combine RBD-targeting therapeutics with those targeting other regions of the S protein, or to combine antibodies recognizing distinct epitopes within the RBD [<xref rid="B102-viruses-11-00060" ref-type="bibr">102</xref>,<xref rid="B128-viruses-11-00060" ref-type="bibr">128</xref>]. Such combinatorial strategies could also dramatically reduce antibody neutralization doses, providing feasible means to combat the continual threat of MERS-CoV.</p><p>Some recent advances have been made in the structure-guided design of anti-MERS-CoV interventions. Structurally designed inhibitors of the 3CL protease have demonstrated potency against MERS-CoV [<xref rid="B129-viruses-11-00060" ref-type="bibr">129</xref>]. Also, a structurally designed S-protein trimer in the optimal prefusion conformation is shown to elicit production of high titers of anti-MERS-CoV neutralizing antibodies [<xref rid="B87-viruses-11-00060" ref-type="bibr">87</xref>]. Indeed, based on the previous studies on the structural design of MERS-CoV RBD, non-neutralizing epitopes in the RBD can be masked, to refocus the immunogenicity of the RBD on the neutralizing epitopes, and thus to enhance its ability to confer immune protection [<xref rid="B93-viruses-11-00060" ref-type="bibr">93</xref>]. Results from these structure-based studies will help to inform the design of innovative RBD-based anti-MERS-CoV vaccines and therapeutics with improved efficacy.</p></sec></body><back><ack><title>Acknowledgments</title><p>This study was supported by the NSFC grant 81571983, and the NIH grants R21AI128311, R01AI137472, and R01AI139092. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</p></ack><notes><title>Author Contributions</title><p>Y.Z. and L.D. drafted the manuscript. Y.Y. and J.H. prepared the figures. Y.Z., S.J., and L.D. reviewed and revised the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no competing interests.</p></notes><ref-list><title>References</title><ref id="B1-viruses-11-00060"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zaki</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>van Boheemen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bestebroer</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Osterhaus</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Fouchier</surname><given-names>R.A.</given-names></name></person-group><article-title>Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia</article-title><source>N. Engl. J. Med.</source><year>2012</year><volume>367</volume><fpage>1814</fpage><lpage>1820</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1211721</pub-id><pub-id pub-id-type="pmid">23075143</pub-id></element-citation></ref><ref id="B2-viruses-11-00060"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sha</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Geng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name></person-group><article-title>Fatality risks for nosocomial outbreaks of Middle East respiratory syndrome coronavirus in the Middle East and South Korea</article-title><source>Arch. Virol.</source><year>2017</year><volume>162</volume><fpage>33</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1007/s00705-016-3062-x</pub-id><pub-id pub-id-type="pmid">27664026</pub-id><pub-id pub-id-type="pmcid">PMC7087023</pub-id></element-citation></ref><ref id="B3-viruses-11-00060"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rivers</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Majumder</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Lofgren</surname><given-names>E.T.</given-names></name></person-group><article-title>Risks of death and severe disease in patients with Middle East respiratory syndrome coronavirus, 2012-2015</article-title><source>Am. J. Epidemiol.</source><year>2016</year><volume>184</volume><fpage>460</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1093/aje/kww013</pub-id><pub-id pub-id-type="pmid">27608662</pub-id><pub-id pub-id-type="pmcid">PMC5023790</pub-id></element-citation></ref><ref id="B4-viruses-11-00060"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Yen</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Wikramaratna</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.H.</given-names></name></person-group><article-title>Impact of comorbidity on fatality rate of patients with Middle East respiratory syndrome</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>11307</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-10402-1</pub-id><pub-id pub-id-type="pmid">28900101</pub-id><pub-id pub-id-type="pmcid">PMC5596001</pub-id></element-citation></ref><ref id="B5-viruses-11-00060"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsuyama</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nishiura</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kutsuna</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hayakawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ohmagari</surname><given-names>N.</given-names></name></person-group><article-title>Clinical determinants of the severity of Middle East respiratory syndrome (MERS): A systematic review and meta-analysis</article-title><source>BMC Public Health</source><year>2016</year><volume>16</volume><elocation-id>1203</elocation-id><pub-id pub-id-type="doi">10.1186/s12889-016-3881-4</pub-id><pub-id pub-id-type="pmid">27899100</pub-id><pub-id pub-id-type="pmcid">PMC5129628</pub-id></element-citation></ref><ref id="B6-viruses-11-00060"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Badawi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ryoo</surname><given-names>S.G.</given-names></name></person-group><article-title>Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): A systematic review and meta-analysis</article-title><source>Int. J. Infect. Dis.</source><year>2016</year><volume>49</volume><fpage>129</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2016.06.015</pub-id><pub-id pub-id-type="pmid">27352628</pub-id><pub-id pub-id-type="pmcid">PMC7110556</pub-id></element-citation></ref><ref id="B7-viruses-11-00060"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Assiri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Al-Tawfiq</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Al-Rabeeah</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Al-Rabiah</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Al-Hajjar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Al-Barrak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Flemban</surname><given-names>H.</given-names></name><name name-style="western"><surname>Al-Nassir</surname><given-names>W.N.</given-names></name><name name-style="western"><surname>Balkhy</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Al-Hakeem</surname><given-names>R.F.</given-names></name><etal/></person-group><article-title>Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: A descriptive study</article-title><source>Lancet Infect. Dis.</source><year>2013</year><volume>13</volume><fpage>752</fpage><lpage>761</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(13)70204-4</pub-id><pub-id pub-id-type="pmid">23891402</pub-id><pub-id pub-id-type="pmcid">PMC7185445</pub-id></element-citation></ref><ref id="B8-viruses-11-00060"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jansen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chiew</surname><given-names>M.</given-names></name><name name-style="western"><surname>Konings</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Ailan</surname><given-names>L.</given-names></name></person-group><article-title>Sex matters - a preliminary analysis of Middle East respiratory syndrome in the Republic of Korea, 2015</article-title><source>West. Pac. Surveill Response J.</source><year>2015</year><volume>6</volume><fpage>68</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.5365/wpsar.2015.6.3.002</pub-id><pub-id pub-id-type="pmcid">PMC4675154</pub-id><pub-id pub-id-type="pmid">26668769</pub-id></element-citation></ref><ref id="B9-viruses-11-00060"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Tandi</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.S.</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak in South Korea, 2015: Epidemiology, characteristics and public health implications</article-title><source>J. Hosp. Infect.</source><year>2017</year><volume>95</volume><fpage>207</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1016/j.jhin.2016.10.008</pub-id><pub-id pub-id-type="pmid">28153558</pub-id><pub-id pub-id-type="pmcid">PMC7114867</pub-id></element-citation></ref><ref id="B10-viruses-11-00060"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Assiri</surname><given-names>A.</given-names></name><name name-style="western"><surname>McGeer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Perl</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Price</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Al Rabeeah</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Alabdullatif</surname><given-names>Z.N.</given-names></name><name name-style="western"><surname>Assad</surname><given-names>M.</given-names></name><name name-style="western"><surname>Almulhim</surname><given-names>A.</given-names></name><name name-style="western"><surname>Makhdoom</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Hospital outbreak of Middle East respiratory syndrome coronavirus</article-title><source>N. Engl. J. Med.</source><year>2013</year><volume>369</volume><fpage>407</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1306742</pub-id><pub-id pub-id-type="pmid">23782161</pub-id><pub-id pub-id-type="pmcid">PMC4029105</pub-id></element-citation></ref><ref id="B11-viruses-11-00060"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alfaraj</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Al-Tawfiq</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Memish</surname><given-names>Z.A.</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus (MERS-CoV) infection during pregnancy: Report of two cases &amp; review of the literature</article-title><source>J. Microbiol. Immunol. Infect.</source><year>2018</year><pub-id pub-id-type="doi">10.1016/j.jmii.2018.04.005</pub-id><pub-id pub-id-type="pmcid">PMC7128238</pub-id><pub-id pub-id-type="pmid">29907538</pub-id></element-citation></ref><ref id="B12-viruses-11-00060"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeong</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Sung</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Sung</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name></person-group><article-title>MERS-CoV infection in a pregnant woman in Korea</article-title><source>J. Korean Med. Sci.</source><year>2017</year><volume>32</volume><fpage>1717</fpage><lpage>1720</lpage><pub-id pub-id-type="doi">10.3346/jkms.2017.32.10.1717</pub-id><pub-id pub-id-type="pmid">28875620</pub-id><pub-id pub-id-type="pmcid">PMC5592190</pub-id></element-citation></ref><ref id="B13-viruses-11-00060"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alfaraj</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Al-Tawfiq</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Altuwaijri</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Memish</surname><given-names>Z.A.</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus in pediatrics: A report of seven cases from Saudi Arabia</article-title><source>Front. Med.</source><year>2018</year><pub-id pub-id-type="doi">10.1007/s11684-017-0603-y</pub-id><pub-id pub-id-type="pmid">29623560</pub-id><pub-id pub-id-type="pmcid">PMC7088593</pub-id></element-citation></ref><ref id="B14-viruses-11-00060"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Assiri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Abedi</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Al</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Bin</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Gerber</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Watson</surname><given-names>J.T.</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus infection during pregnancy: A Report of 5 cases from Saudi Arabia</article-title><source>Clin. Infect. Dis.</source><year>2016</year><volume>63</volume><fpage>951</fpage><lpage>953</lpage><pub-id pub-id-type="doi">10.1093/cid/ciw412</pub-id><pub-id pub-id-type="pmid">27358348</pub-id><pub-id pub-id-type="pmcid">PMC5812010</pub-id></element-citation></ref><ref id="B15-viruses-11-00060"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>J.Y.</given-names></name></person-group><article-title>An outbreak of Middle East respiratory syndrome coronavirus infection in South Korea, 2015</article-title><source>Yonsei Med. J.</source><year>2015</year><volume>56</volume><fpage>1174</fpage><lpage>1176</lpage><pub-id pub-id-type="doi">10.3349/ymj.2015.56.5.1174</pub-id><pub-id pub-id-type="pmid">26256957</pub-id><pub-id pub-id-type="pmcid">PMC4541644</pub-id></element-citation></ref><ref id="B16-viruses-11-00060"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>N.S.</given-names></name></person-group><article-title>Probable transmission chains of Middle East respiratory syndrome coronavirus and the multiple generations of secondary infection in South Korea</article-title><source>Int. J. Infect. Dis.</source><year>2015</year><volume>38</volume><fpage>65</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2015.07.014</pub-id><pub-id pub-id-type="pmid">26216766</pub-id><pub-id pub-id-type="pmcid">PMC7110481</pub-id></element-citation></ref><ref id="B17-viruses-11-00060"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anthony</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Gilardi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Menachery</surname><given-names>V.D.</given-names></name><name name-style="western"><surname>Goldstein</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ssebide</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mbabazi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Navarrete-Macias</surname><given-names>I.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hicks</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Further evidence for bats as the evolutionary source of Middle East respiratory syndrome coronavirus</article-title><source>MBio</source><year>2017</year><volume>8</volume><fpage>e00373-17</fpage><pub-id pub-id-type="doi">10.1128/mBio.00373-17</pub-id><pub-id pub-id-type="pmid">28377531</pub-id><pub-id pub-id-type="pmcid">PMC5380844</pub-id></element-citation></ref><ref id="B18-viruses-11-00060"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xuan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Han</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26</article-title><source>Cell Host Microbe</source><year>2014</year><volume>16</volume><fpage>328</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2014.08.009</pub-id><pub-id pub-id-type="pmid">25211075</pub-id><pub-id pub-id-type="pmcid">PMC7104937</pub-id></element-citation></ref><ref id="B19-viruses-11-00060"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name></person-group><article-title>Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>12516</fpage><lpage>12521</lpage><pub-id pub-id-type="doi">10.1073/pnas.1405889111</pub-id><pub-id pub-id-type="pmid">25114257</pub-id><pub-id pub-id-type="pmcid">PMC4151778</pub-id></element-citation></ref><ref id="B20-viruses-11-00060"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munster</surname><given-names>V.J.</given-names></name><name name-style="western"><surname>Adney</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Van Doremalen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>V.R.</given-names></name><name name-style="western"><surname>Miazgowicz</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Milne-Price</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bushmaker</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rosenke</surname><given-names>R.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hawkinson</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Replication and shedding of MERS-CoV in Jamaican fruit bats (Artibeus jamaicensis)</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>21878</fpage><pub-id pub-id-type="doi">10.1038/srep21878</pub-id><pub-id pub-id-type="pmid">26899616</pub-id><pub-id pub-id-type="pmcid">PMC4761889</pub-id></element-citation></ref><ref id="B21-viruses-11-00060"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Geng</surname><given-names>Q.B.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>G.J.</given-names></name><etal/></person-group><article-title>Discovery of novel bat coronaviruses in south China that use the same receptor as Middle East respiratory syndrome coronavirus</article-title><source>J. Virol.</source><year>2018</year><volume>92</volume><fpage>e00116-18</fpage><pub-id pub-id-type="doi">10.1128/JVI.00116-18</pub-id><pub-id pub-id-type="pmid">29669833</pub-id><pub-id pub-id-type="pmcid">PMC6002729</pub-id></element-citation></ref><ref id="B22-viruses-11-00060"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Woo</surname><given-names>P.C.Y.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>S.K.P.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>E.Y.M.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>K.Y.</given-names></name></person-group><article-title>Rapid detection of MERS coronavirus-like viruses in bats: Pote1ntial for tracking MERS coronavirus transmission and animal origin</article-title><source>Emerg. Microbes Infect.</source><year>2018</year><volume>7</volume><fpage>18</fpage><pub-id pub-id-type="doi">10.1038/s41426-017-0016-7</pub-id><pub-id pub-id-type="pmid">29511173</pub-id><pub-id pub-id-type="pmcid">PMC5841240</pub-id></element-citation></ref><ref id="B23-viruses-11-00060"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lau</surname><given-names>S.K.P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Luk</surname><given-names>H.K.H.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>K.S.M.</given-names></name><name name-style="western"><surname>He</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>R.Y.Y.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>A.C.P.</given-names></name><etal/></person-group><article-title>Receptor usage of a novel bat lineage C Betacoronavirus reveals evolution of Middle East respiratory syndrome-related coronavirus spike proteins for human dipeptidyl peptidase 4 binding</article-title><source>J. Infect. Dis.</source><year>2018</year><volume>218</volume><fpage>197</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiy018</pub-id><pub-id pub-id-type="pmid">29346682</pub-id><pub-id pub-id-type="pmcid">PMC7107427</pub-id></element-citation></ref><ref id="B24-viruses-11-00060"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dudas</surname><given-names>G.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bedford</surname><given-names>T.</given-names></name></person-group><article-title>MERS-CoV spillover at the camel-human interface</article-title><source>Elife</source><year>2018</year><volume>7</volume><fpage>e31257</fpage><pub-id pub-id-type="doi">10.7554/eLife.31257</pub-id><pub-id pub-id-type="pmid">29336306</pub-id><pub-id pub-id-type="pmcid">PMC5777824</pub-id></element-citation></ref><ref id="B25-viruses-11-00060"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yusof</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Eltahir</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Serhan</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Hashem</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Elsayed</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Marzoug</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Abdelazim</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Bensalah</surname><given-names>O.K.</given-names></name><name name-style="western"><surname>Al Muhairi</surname><given-names>S.S.</given-names></name></person-group><article-title>Prevalence of Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels in Abu Dhabi Emirate, United Arab Emirates</article-title><source>Virus Genes</source><year>2015</year><volume>50</volume><fpage>509</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1007/s11262-015-1174-0</pub-id><pub-id pub-id-type="pmid">25653016</pub-id><pub-id pub-id-type="pmcid">PMC7088545</pub-id></element-citation></ref><ref id="B26-viruses-11-00060"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haagmans</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Al Dhahiry</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Reusken</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Raj</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Galiano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Myers</surname><given-names>R.</given-names></name><name name-style="western"><surname>Godeke</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Jonges</surname><given-names>M.</given-names></name><name name-style="western"><surname>Farag</surname><given-names>E.</given-names></name><name name-style="western"><surname>Diab</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Middle East respiratory syndrome coronavirus in dromedary camels: An outbreak investigation</article-title><source>Lancet Infect. Dis.</source><year>2014</year><volume>14</volume><fpage>140</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(13)70690-X</pub-id><pub-id pub-id-type="pmid">24355866</pub-id><pub-id pub-id-type="pmcid">PMC7106553</pub-id></element-citation></ref><ref id="B27-viruses-11-00060"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alshukairi</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nehdi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Baharoon</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Layqah</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bokhari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Al Johani</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Samman</surname><given-names>N.</given-names></name><name name-style="western"><surname>Boudjelal</surname><given-names>M.</given-names></name><etal/></person-group><article-title>High prevalence of MERS-CoV infection in camel workers in Saudi Arabia</article-title><source>MBio</source><year>2018</year><volume>9</volume><fpage>e01985-18</fpage><pub-id pub-id-type="doi">10.1128/mBio.01985-18</pub-id><pub-id pub-id-type="pmid">30377284</pub-id><pub-id pub-id-type="pmcid">PMC6212820</pub-id></element-citation></ref><ref id="B28-viruses-11-00060"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harcourt</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Rudoler</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tamin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leshem</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rasis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Giladi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Haynes</surname><given-names>L.M.</given-names></name></person-group><article-title>The prevalence of Middle East respiratory syndrome coronavirus (MERS-CoV) antibodies in dromedary camels in Israel</article-title><source>Zoonoses Public Health</source><year>2018</year><pub-id pub-id-type="doi">10.1111/zph.12482</pub-id><pub-id pub-id-type="pmid">29855166</pub-id><pub-id pub-id-type="pmcid">PMC6274617</pub-id></element-citation></ref><ref id="B29-viruses-11-00060"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saqib</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sieberg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Mansoor</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Zohaib</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lattwein</surname><given-names>E.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Drosten</surname><given-names>C.</given-names></name><name name-style="western"><surname>Corman</surname><given-names>V.M.</given-names></name></person-group><article-title>Serologic evidence for MERS-CoV infection in dromedary camels, Punjab, Pakistan, 2012-2015</article-title><source>Emerg. Infect. Dis.</source><year>2017</year><volume>23</volume><fpage>550</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.3201/eid2303.161285</pub-id><pub-id pub-id-type="pmid">28221127</pub-id><pub-id pub-id-type="pmcid">PMC5382745</pub-id></element-citation></ref><ref id="B30-viruses-11-00060"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harrath</surname><given-names>R.</given-names></name><name name-style="western"><surname>Abu Duhier</surname><given-names>F.M.</given-names></name></person-group><article-title>Sero-prevalence of Middle East respiratory syndrome coronavirus (MERS-CoV) specific antibodies in dromedary camels in Tabuk, Saudi Arabia</article-title><source>J. Med. Virol.</source><year>2018</year><volume>90</volume><fpage>1285</fpage><lpage>1289</lpage><pub-id pub-id-type="doi">10.1002/jmv.25186</pub-id><pub-id pub-id-type="pmid">29663439</pub-id><pub-id pub-id-type="pmcid">PMC7166535</pub-id></element-citation></ref><ref id="B31-viruses-11-00060"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falzarano</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kamissoko</surname><given-names>B.</given-names></name><name name-style="western"><surname>de Wit</surname><given-names>E.</given-names></name><name name-style="western"><surname>Maiga</surname><given-names>O.</given-names></name><name name-style="western"><surname>Cronin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Samake</surname><given-names>K.</given-names></name><name name-style="western"><surname>Traore</surname><given-names>A.</given-names></name><name name-style="western"><surname>Milne-Price</surname><given-names>S.</given-names></name><name name-style="western"><surname>Munster</surname><given-names>V.J.</given-names></name><name name-style="western"><surname>Sogoba</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Dromedary camels in northern Mali have high seropositivity to MERS-CoV</article-title><source>One Health</source><year>2017</year><volume>3</volume><fpage>41</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.onehlt.2017.03.003</pub-id><pub-id pub-id-type="pmid">28616502</pub-id><pub-id pub-id-type="pmcid">PMC5454179</pub-id></element-citation></ref><ref id="B32-viruses-11-00060"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>M.</given-names></name><name name-style="western"><surname>El-Shesheny</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kandeil</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shehata</surname><given-names>M.</given-names></name><name name-style="western"><surname>Elsokary</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gomaa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>N.</given-names></name><name name-style="western"><surname>El</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>El-Taweel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sobhy</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Cross-sectional surveillance of Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels and other mammals in Egypt, August 2015 to January 2016</article-title><source>Euro. Surveill</source><year>2017</year><volume>22</volume><fpage>30487</fpage><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2017.22.11.30487</pub-id><pub-id pub-id-type="pmid">28333616</pub-id><pub-id pub-id-type="pmcid">PMC5356426</pub-id></element-citation></ref><ref id="B33-viruses-11-00060"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Shehata</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Gomaa</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Kandeil</surname><given-names>A.</given-names></name><name name-style="western"><surname>El-Shesheny</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kayed</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>El-Taweel</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Atea</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bagato</surname><given-names>O.</given-names></name><etal/></person-group><article-title>Systematic, active surveillance for Middle East respiratory syndrome coronavirus in camels in Egypt</article-title><source>Emerg. Microbes Infect.</source><year>2017</year><fpage>6</fpage><pub-id pub-id-type="doi">10.1038/emi.2016.130</pub-id><pub-id pub-id-type="pmid">28050021</pub-id><pub-id pub-id-type="pmcid">PMC5285495</pub-id></element-citation></ref><ref id="B34-viruses-11-00060"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deem</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Fevre</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Kinnaird</surname><given-names>M.</given-names></name><name name-style="western"><surname>Browne</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Muloi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Godeke</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Koopmans</surname><given-names>M.</given-names></name><name name-style="western"><surname>Reusken</surname><given-names>C.B.</given-names></name></person-group><article-title>Serological evidence of MERS-CoV antibodies in dromedary camels (Camelus dromedaries) in Laikipia county, Kenya</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0140125</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0140125</pub-id><pub-id pub-id-type="pmid">26473733</pub-id><pub-id pub-id-type="pmcid">PMC4608777</pub-id></element-citation></ref><ref id="B35-viruses-11-00060"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conzade</surname><given-names>R.</given-names></name><name name-style="western"><surname>Grant</surname><given-names>R.</given-names></name><name name-style="western"><surname>Malik</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Elkholy</surname><given-names>A.</given-names></name><name name-style="western"><surname>Elhakim</surname><given-names>M.</given-names></name><name name-style="western"><surname>Samhouri</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ben Embarek</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Van Kerkhove</surname><given-names>M.D.</given-names></name></person-group><article-title>Reported direct and indirect contact with dromedary camels among laboratory-confirmed MERS-CoV cases</article-title><source>Viruses</source><year>2018</year><volume>10</volume><elocation-id>425</elocation-id><pub-id pub-id-type="doi">10.3390/v10080425</pub-id><pub-id pub-id-type="pmcid">PMC6115845</pub-id><pub-id pub-id-type="pmid">30104551</pub-id></element-citation></ref><ref id="B36-viruses-11-00060"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hui</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Azhar</surname><given-names>E.I.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Memish</surname><given-names>Z.A.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Zumla</surname><given-names>A.</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus: Risk factors and determinants of primary, household, and nosocomial transmission</article-title><source>Lancet Infect. Dis.</source><year>2018</year><volume>18</volume><fpage>e217</fpage><lpage>e227</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(18)30127-0</pub-id><pub-id pub-id-type="pmid">29680581</pub-id><pub-id pub-id-type="pmcid">PMC7164784</pub-id></element-citation></ref><ref id="B37-viruses-11-00060"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amer</surname><given-names>H.</given-names></name><name name-style="western"><surname>Alqahtani</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Alzoman</surname><given-names>H.</given-names></name><name name-style="western"><surname>Aljerian</surname><given-names>N.</given-names></name><name name-style="western"><surname>Memish</surname><given-names>Z.A.</given-names></name></person-group><article-title>Unusual presentation of Middle East respiratory syndrome coronavirus leading to a large outbreak in Riyadh during 2017</article-title><source>Am. J. Infect. Control.</source><year>2018</year><volume>46</volume><fpage>1022</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1016/j.ajic.2018.02.023</pub-id><pub-id pub-id-type="pmid">29661625</pub-id><pub-id pub-id-type="pmcid">PMC7115299</pub-id></element-citation></ref><ref id="B38-viruses-11-00060"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Heo</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cheon</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Outbreaks of Middle East respiratory syndrome in two hospitals initiated by a single patient in Daejeon, South Korea</article-title><source>Infect. Chemother.</source><year>2016</year><volume>48</volume><fpage>99</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.3947/ic.2016.48.2.99</pub-id><pub-id pub-id-type="pmid">27433380</pub-id><pub-id pub-id-type="pmcid">PMC4945733</pub-id></element-citation></ref><ref id="B39-viruses-11-00060"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Ha</surname><given-names>Y.E.</given-names></name><name name-style="western"><surname>Park</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>C.I.</given-names></name><name name-style="western"><surname>Jo</surname><given-names>I.J.</given-names></name><etal/></person-group><article-title>MERS-CoV outbreak following a single patient exposure in an emergency room in South Korea: An epidemiological outbreak study</article-title><source>Lancet</source><year>2016</year><volume>388</volume><fpage>994</fpage><lpage>1001</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)30623-7</pub-id><pub-id pub-id-type="pmid">27402381</pub-id><pub-id pub-id-type="pmcid">PMC7159268</pub-id></element-citation></ref><ref id="B40-viruses-11-00060"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hastings</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Tokars</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Abdel Aziz</surname><given-names>I.Z.</given-names></name><name name-style="western"><surname>Alkhaldi</surname><given-names>K.Z.</given-names></name><name name-style="western"><surname>Bensadek</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Alraddadi</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Jokhdar</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jernigan</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Garout</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Tomczyk</surname><given-names>S.M.</given-names></name><etal/></person-group><article-title>Outbreak of Middle East respiratory syndrome at tertiary care hospital, Jeddah, Saudi Arabia, 2014</article-title><source>Emerg. Infect. Dis.</source><year>2016</year><volume>22</volume><fpage>794</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.3201/eid2205.151797</pub-id><pub-id pub-id-type="pmid">27089550</pub-id><pub-id pub-id-type="pmcid">PMC4861521</pub-id></element-citation></ref><ref id="B41-viruses-11-00060"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hunter</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Aden</surname><given-names>B.</given-names></name><name name-style="western"><surname>Al</surname><given-names>B.Z.</given-names></name><name name-style="western"><surname>Al</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Abu</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Khudair</surname><given-names>A.</given-names></name><name name-style="western"><surname>Al</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>El</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Imambaccus</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Transmission of Middle East respiratory syndrome coronavirus infections in healthcare settings, Abu Dhabi</article-title><source>Emerg. Infect. Dis.</source><year>2016</year><volume>22</volume><fpage>647</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.3201/eid2204.151615</pub-id><pub-id pub-id-type="pmid">26981708</pub-id><pub-id pub-id-type="pmcid">PMC4806977</pub-id></element-citation></ref><ref id="B42-viruses-11-00060"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harriman</surname><given-names>K.</given-names></name><name name-style="western"><surname>Brosseau</surname><given-names>L.</given-names></name><name name-style="western"><surname>Trivedi</surname><given-names>K.</given-names></name></person-group><article-title>Hospital-associated Middle East respiratory syndrome coronavirus infections</article-title><source>N. Engl. J. Med.</source><year>2013</year><volume>369</volume><fpage>1761</fpage><pub-id pub-id-type="pmid">24171525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc1311004</pub-id></element-citation></ref><ref id="B43-viruses-11-00060"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Memish</surname><given-names>Z.A.</given-names></name><name name-style="western"><surname>Al-Tawfiq</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Assiri</surname><given-names>A.</given-names></name></person-group><article-title>Hospital-associated Middle East respiratory syndrome coronavirus infections</article-title><source>N. Engl. J. Med.</source><year>2013</year><volume>369</volume><fpage>1761</fpage><lpage>1762</lpage><pub-id pub-id-type="doi">10.1056/NEJMc1308698</pub-id><pub-id pub-id-type="pmid">24171524</pub-id></element-citation></ref><ref id="B44-viruses-11-00060"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Memish</surname><given-names>Z.A.</given-names></name><name name-style="western"><surname>Zumla</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Al-Hakeem</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Al-Rabeeah</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Stephens</surname><given-names>G.M.</given-names></name></person-group><article-title>Family cluster of Middle East respiratory syndrome coronavirus infections</article-title><source>N. Engl. J. Med.</source><year>2013</year><volume>368</volume><fpage>2487</fpage><lpage>2494</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1303729</pub-id><pub-id pub-id-type="pmid">23718156</pub-id></element-citation></ref><ref id="B45-viruses-11-00060"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Tawfiq</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Auwaerter</surname><given-names>P.G.</given-names></name></person-group><article-title>Healthcare-associated infections: The hallmark of Middle East respiratory syndrome coronavirus with review of the literature</article-title><source>J. Hosp. Infect.</source><year>2019</year><volume>101</volume><fpage>20</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.jhin.2018.05.021</pub-id><pub-id pub-id-type="pmid">29864486</pub-id><pub-id pub-id-type="pmcid">PMC7114594</pub-id></element-citation></ref><ref id="B46-viruses-11-00060"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guery</surname><given-names>B.</given-names></name><name name-style="western"><surname>Poissy</surname><given-names>J.</given-names></name><name name-style="western"><surname>El</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Sejourne</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ettahar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lemaire</surname><given-names>X.</given-names></name><name name-style="western"><surname>Vuotto</surname><given-names>F.</given-names></name><name name-style="western"><surname>Goffard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Behillil</surname><given-names>S.</given-names></name><name name-style="western"><surname>Enouf</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Clinical features and viral diagnosis of two cases of infection with Middle East respiratory syndrome coronavirus: A report of nosocomial transmission</article-title><source>Lancet</source><year>2013</year><volume>381</volume><fpage>2265</fpage><lpage>2272</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(13)60982-4</pub-id><pub-id pub-id-type="pmid">23727167</pub-id><pub-id pub-id-type="pmcid">PMC7159298</pub-id></element-citation></ref><ref id="B47-viruses-11-00060"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arabi</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Arifi</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Balkhy</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Najm</surname><given-names>H.</given-names></name><name name-style="western"><surname>Aldawood</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Ghabashi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Alothman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khaldi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Al</surname><given-names>R.B.</given-names></name></person-group><article-title>Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection</article-title><source>Ann. Intern. Med.</source><year>2014</year><volume>160</volume><fpage>389</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.7326/M13-2486</pub-id><pub-id pub-id-type="pmid">24474051</pub-id></element-citation></ref><ref id="B48-viruses-11-00060"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Poon</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus</article-title><source>Sci. Adv.</source><year>2017</year><volume>3</volume><fpage>eaao4966</fpage><pub-id pub-id-type="doi">10.1126/sciadv.aao4966</pub-id><pub-id pub-id-type="pmid">29152574</pub-id><pub-id pub-id-type="pmcid">PMC5687858</pub-id></element-citation></ref><ref id="B49-viruses-11-00060"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Payne</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Iblan</surname><given-names>I.</given-names></name><name name-style="western"><surname>Rha</surname><given-names>B.</given-names></name><name name-style="western"><surname>Alqasrawi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Haddadin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Al</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Alsanouri</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Harcourt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Miao</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Persistence of antibodies against Middle East respiratory syndrome coronavirus</article-title><source>Emerg. Infect. Dis.</source><year>2016</year><volume>22</volume><fpage>1824</fpage><lpage>1826</lpage><pub-id pub-id-type="doi">10.3201/eid2210.160706</pub-id><pub-id pub-id-type="pmid">27332149</pub-id><pub-id pub-id-type="pmcid">PMC5038413</pub-id></element-citation></ref><ref id="B50-viruses-11-00060"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muller</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>B.</given-names></name><name name-style="western"><surname>Corman</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Al-Masri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Turkestani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ritz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sieberg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aldabbagh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bosch</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Lattwein</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: A nationwide, cross-sectional, serological study</article-title><source>Lancet Infect. Dis.</source><year>2015</year><volume>15</volume><fpage>559</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(15)70090-3</pub-id><pub-id pub-id-type="pmid">25863564</pub-id><pub-id pub-id-type="pmcid">PMC7185864</pub-id></element-citation></ref><ref id="B51-viruses-11-00060"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arabi</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Hajeer</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Luke</surname><given-names>T.</given-names></name><name name-style="western"><surname>Raviprakash</surname><given-names>K.</given-names></name><name name-style="western"><surname>Balkhy</surname><given-names>H.</given-names></name><name name-style="western"><surname>Johani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Al-Dawood</surname><given-names>A.</given-names></name><name name-style="western"><surname>Al-Qahtani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Al-Omari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Al-Hameed</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia</article-title><source>Emerg. Infect. Dis.</source><year>2016</year><volume>22</volume><fpage>1554</fpage><lpage>1561</lpage><pub-id pub-id-type="doi">10.3201/eid2209.151164</pub-id><pub-id pub-id-type="pmid">27532807</pub-id><pub-id pub-id-type="pmcid">PMC4994343</pub-id></element-citation></ref><ref id="B52-viruses-11-00060"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arabi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Balkhy</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hajeer</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Bouchama</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hayden</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Al-Omari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Al-Hameed</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Taha</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shindo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Whitehead</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: A study protocol</article-title><source>Springerplus</source><year>2015</year><volume>4</volume><fpage>709</fpage><pub-id pub-id-type="doi">10.1186/s40064-015-1490-9</pub-id><pub-id pub-id-type="pmid">26618098</pub-id><pub-id pub-id-type="pmcid">PMC4653124</pub-id></element-citation></ref><ref id="B53-viruses-11-00060"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ko</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Seok</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Ha</surname><given-names>Y.E.</given-names></name><name name-style="western"><surname>Baek</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>E.S.</given-names></name><etal/></person-group><article-title>Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: A single centre experience</article-title><source>Antivir. Ther.</source><year>2018</year><volume>23</volume><fpage>617</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.3851/IMP3243</pub-id><pub-id pub-id-type="pmid">29923831</pub-id></element-citation></ref><ref id="B54-viruses-11-00060"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beigel</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Voell</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Raviprakash</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Luke</surname><given-names>T.</given-names></name><name name-style="western"><surname>Davey</surname><given-names>R.T.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: A phase 1 randomised, double-blind, single-dose-escalation study</article-title><source>Lancet Infect. Dis.</source><year>2018</year><volume>18</volume><fpage>410</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(18)30002-1</pub-id><pub-id pub-id-type="pmid">29329957</pub-id><pub-id pub-id-type="pmcid">PMC5871563</pub-id></element-citation></ref><ref id="B55-viruses-11-00060"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name></person-group><article-title>Prospects for a MERS-CoV spike vaccine</article-title><source>Expert. Rev. Vaccines</source><year>2018</year><volume>17</volume><fpage>677</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1080/14760584.2018.1506702</pub-id><pub-id pub-id-type="pmid">30058403</pub-id><pub-id pub-id-type="pmcid">PMC6355461</pub-id></element-citation></ref><ref id="B56-viruses-11-00060"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name></person-group><article-title>Current advancements and potential strategies in the development of MERS-CoV vaccines</article-title><source>Expert. Rev. Vaccines</source><year>2014</year><volume>13</volume><fpage>761</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1586/14760584.2014.912134</pub-id><pub-id pub-id-type="pmid">24766432</pub-id><pub-id pub-id-type="pmcid">PMC4241375</pub-id></element-citation></ref><ref id="B57-viruses-11-00060"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>To</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>V.C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>K.Y.</given-names></name></person-group><article-title>Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic?</article-title><source>J. Infect.</source><year>2012</year><volume>65</volume><fpage>477</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2012.10.002</pub-id><pub-id pub-id-type="pmid">23072791</pub-id><pub-id pub-id-type="pmcid">PMC7112628</pub-id></element-citation></ref><ref id="B58-viruses-11-00060"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>MERS-CoV spike protein: A key target for antivirals</article-title><source>Expert. Opin. Ther. Targets</source><year>2017</year><volume>21</volume><fpage>131</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1080/14728222.2017.1271415</pub-id><pub-id pub-id-type="pmid">27936982</pub-id><pub-id pub-id-type="pmcid">PMC5457961</pub-id></element-citation></ref><ref id="B59-viruses-11-00060"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Boheemen</surname><given-names>S.</given-names></name><name name-style="western"><surname>de Graaf</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lauber</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bestebroer</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Raj</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Zaki</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Osterhaus</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Haagmans</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Gorbalenya</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Snijder</surname><given-names>E.J.</given-names></name><etal/></person-group><article-title>Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans</article-title><source>MBio</source><year>2012</year><volume>3</volume><fpage>e00473-12</fpage><pub-id pub-id-type="doi">10.1128/mBio.00473-12</pub-id><pub-id pub-id-type="pmid">23170002</pub-id><pub-id pub-id-type="pmcid">PMC3509437</pub-id></element-citation></ref><ref id="B60-viruses-11-00060"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Almazan</surname><given-names>F.</given-names></name><name name-style="western"><surname>DeDiego</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Sola</surname><given-names>I.</given-names></name><name name-style="western"><surname>Zuniga</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nieto-Torres</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Marquez-Jurado</surname><given-names>S.</given-names></name><name name-style="western"><surname>Andres</surname><given-names>G.</given-names></name><name name-style="western"><surname>Enjuanes</surname><given-names>L.</given-names></name></person-group><article-title>Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate</article-title><source>MBio</source><year>2013</year><volume>4</volume><fpage>e00650-13</fpage><pub-id pub-id-type="doi">10.1128/mBio.00650-13</pub-id><pub-id pub-id-type="pmid">24023385</pub-id><pub-id pub-id-type="pmcid">PMC3774192</pub-id></element-citation></ref><ref id="B61-viruses-11-00060"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scobey</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yount</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Sims</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Donaldson</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Agnihothram</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Menachery</surname><given-names>V.D.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Swanstrom</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bove</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.D.</given-names></name><etal/></person-group><article-title>Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2013</year><volume>110</volume><fpage>16157</fpage><lpage>16162</lpage><pub-id pub-id-type="doi">10.1073/pnas.1311542110</pub-id><pub-id pub-id-type="pmid">24043791</pub-id><pub-id pub-id-type="pmcid">PMC3791741</pub-id></element-citation></ref><ref id="B62-viruses-11-00060"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakagawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Narayanan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wada</surname><given-names>M.</given-names></name><name name-style="western"><surname>Popov</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Cajimat</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Makino</surname><given-names>S.</given-names></name></person-group><article-title>The endonucleolytic RNA cleavage function of nsp1 of Middle East respiratory syndrome coronavirus promotes the production of infectious virus particles in specific human cell lines</article-title><source>J. Virol.</source><year>2018</year><volume>92</volume><fpage>e01157-18</fpage><pub-id pub-id-type="doi">10.1128/JVI.01157-18</pub-id><pub-id pub-id-type="pmid">30111568</pub-id><pub-id pub-id-type="pmcid">PMC6189501</pub-id></element-citation></ref><ref id="B63-viruses-11-00060"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Terada</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kawachi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Matsuura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kamitani</surname><given-names>W.</given-names></name></person-group><article-title>MERS coronavirus nsp1 participates in an efficient propagation through a specific interaction with viral RNA</article-title><source>Virology</source><year>2017</year><volume>511</volume><fpage>95</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2017.08.026</pub-id><pub-id pub-id-type="pmid">28843094</pub-id><pub-id pub-id-type="pmcid">PMC7118922</pub-id></element-citation></ref><ref id="B64-viruses-11-00060"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Menachery</surname><given-names>V.D.</given-names></name><name name-style="western"><surname>Gralinski</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>H.D.</given-names></name><name name-style="western"><surname>Dinnon</surname><given-names>K.H.</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Leist</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Yount</surname><given-names>B.L.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Graham</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>McAnarney</surname><given-names>E.T.</given-names></name><name name-style="western"><surname>Stratton</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Cockrell</surname><given-names>A.S.</given-names></name><etal/></person-group><article-title>Middle East respiratory syndrome coronavirus nonstructural protein 16 Is necessary for interferon resistance and viral pathogenesis</article-title><source>mSphere</source><year>2017</year><volume>2</volume><fpage>e00346-17</fpage><pub-id pub-id-type="doi">10.1128/mSphere.00346-17</pub-id><pub-id pub-id-type="pmid">29152578</pub-id><pub-id pub-id-type="pmcid">PMC5687918</pub-id></element-citation></ref><ref id="B65-viruses-11-00060"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ming</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>Z.</given-names></name></person-group><article-title>Structural and biochemical characterization of endoribonuclease Nsp15 encoded by Middle East respiratory syndrome coronavirus</article-title><source>J. Virol.</source><year>2018</year><volume>92</volume><fpage>e00893-18</fpage><pub-id pub-id-type="doi">10.1128/JVI.00893-18</pub-id><pub-id pub-id-type="pmid">30135128</pub-id><pub-id pub-id-type="pmcid">PMC6206473</pub-id></element-citation></ref><ref id="B66-viruses-11-00060"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Batool</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Patra</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Yesudhas</surname><given-names>D.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>S.</given-names></name></person-group><article-title>Structural insights into the Middle East respiratory syndrome coronavirus 4a protein and its dsRNA binding mechanism</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><fpage>11362</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-11736-6</pub-id><pub-id pub-id-type="pmid">28900197</pub-id><pub-id pub-id-type="pmcid">PMC5596018</pub-id></element-citation></ref><ref id="B67-viruses-11-00060"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rabouw</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Langereis</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Knaap</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Dalebout</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Canton</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sola</surname><given-names>I.</given-names></name><name name-style="western"><surname>Enjuanes</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bredenbeek</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Kikkert</surname><given-names>M.</given-names></name><name name-style="western"><surname>de Groot</surname><given-names>R.J.</given-names></name><etal/></person-group><article-title>Middle East respiratory coronavirus accessory protein 4a inhibits PKR-mediated antiviral stress responses</article-title><source>PLoS Pathog.</source><year>2016</year><volume>12</volume><elocation-id>e1005982</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1005982</pub-id><pub-id pub-id-type="pmid">27783669</pub-id><pub-id pub-id-type="pmcid">PMC5081173</pub-id></element-citation></ref><ref id="B68-viruses-11-00060"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakagawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Narayanan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wada</surname><given-names>M.</given-names></name><name name-style="western"><surname>Makino</surname><given-names>S.</given-names></name></person-group><article-title>Inhibition of stress granule formation by Middle East respiratory syndrome coronavirus 4a accessory protein facilitates viral translation, leading to efficient virus replication</article-title><source>J. Virol.</source><year>2018</year><volume>92</volume><fpage>e00902-18</fpage><pub-id pub-id-type="doi">10.1128/JVI.00902-18</pub-id><pub-id pub-id-type="pmid">30068649</pub-id><pub-id pub-id-type="pmcid">PMC6158436</pub-id></element-citation></ref><ref id="B69-viruses-11-00060"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Canton</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fehr</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Fernandez-Delgado</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gutierrez-Alvarez</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Sanchez-Aparicio</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Garcia-Sastre</surname><given-names>A.</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Enjuanes</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sola</surname><given-names>I.</given-names></name></person-group><article-title>MERS-CoV 4b protein interferes with the NF-kappaB-dependent innate immune response during infection</article-title><source>PLoS Pathog.</source><year>2018</year><volume>14</volume><elocation-id>e1006838</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1006838</pub-id><pub-id pub-id-type="pmid">29370303</pub-id><pub-id pub-id-type="pmcid">PMC5800688</pub-id></element-citation></ref><ref id="B70-viruses-11-00060"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Li</surname><given-names>K.</given-names></name><name name-style="western"><surname>Barlan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fehr</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S.</given-names></name><name name-style="western"><surname>McCray</surname><given-names>P.B.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Gallagher</surname><given-names>T.</given-names></name></person-group><article-title>Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2016</year><volume>113</volume><fpage>12262</fpage><lpage>12267</lpage><pub-id pub-id-type="doi">10.1073/pnas.1608147113</pub-id><pub-id pub-id-type="pmid">27791014</pub-id><pub-id pub-id-type="pmcid">PMC5086990</pub-id></element-citation></ref><ref id="B71-viruses-11-00060"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Millet</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Whittaker</surname><given-names>G.R.</given-names></name></person-group><article-title>Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>15214</fpage><lpage>15219</lpage><pub-id pub-id-type="doi">10.1073/pnas.1407087111</pub-id><pub-id pub-id-type="pmid">25288733</pub-id><pub-id pub-id-type="pmcid">PMC4210292</pub-id></element-citation></ref><ref id="B72-viruses-11-00060"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name></person-group><article-title>Structure, function, and evolution of coronavirus spike proteins</article-title><source>Annu. Rev. Virol.</source><year>2016</year><volume>3</volume><fpage>237</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1146/annurev-virology-110615-042301</pub-id><pub-id pub-id-type="pmid">27578435</pub-id><pub-id pub-id-type="pmcid">PMC5457962</pub-id></element-citation></ref><ref id="B73-viruses-11-00060"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G.F.</given-names></name></person-group><article-title>MERS-CoV spike protein: Targets for vaccines and therapeutics</article-title><source>Antiviral Res.</source><year>2016</year><volume>133</volume><fpage>165</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2016.07.015</pub-id><pub-id pub-id-type="pmid">27468951</pub-id><pub-id pub-id-type="pmcid">PMC7113765</pub-id></element-citation></ref><ref id="B74-viruses-11-00060"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raj</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Mou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Smits</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Dekkers</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Dijkman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Muth</surname><given-names>D.</given-names></name><name name-style="western"><surname>Demmers</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Zaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fouchier</surname><given-names>R.A.</given-names></name><etal/></person-group><article-title>Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC</article-title><source>Nature</source><year>2013</year><volume>495</volume><fpage>251</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1038/nature12005</pub-id><pub-id pub-id-type="pmid">23486063</pub-id><pub-id pub-id-type="pmcid">PMC7095326</pub-id></element-citation></ref><ref id="B75-viruses-11-00060"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Geng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus</article-title><source>J. Virol.</source><year>2013</year><volume>87</volume><fpage>13134</fpage><lpage>13140</lpage><pub-id pub-id-type="doi">10.1128/JVI.02433-13</pub-id><pub-id pub-id-type="pmid">24067982</pub-id><pub-id pub-id-type="pmcid">PMC3838252</pub-id></element-citation></ref><ref id="B76-viruses-11-00060"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor</article-title><source>Nat. Commun.</source><year>2014</year><volume>5</volume><fpage>3067</fpage><pub-id pub-id-type="doi">10.1038/ncomms4067</pub-id><pub-id pub-id-type="pmid">24473083</pub-id><pub-id pub-id-type="pmcid">PMC7091805</pub-id></element-citation></ref><ref id="B77-viruses-11-00060"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Rajashankar</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Agnihothram</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name></person-group><article-title>Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus</article-title><source>J. Virol.</source><year>2013</year><volume>87</volume><fpage>10777</fpage><lpage>10783</lpage><pub-id pub-id-type="doi">10.1128/JVI.01756-13</pub-id><pub-id pub-id-type="pmid">23903833</pub-id><pub-id pub-id-type="pmcid">PMC3807420</pub-id></element-citation></ref><ref id="B78-viruses-11-00060"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsuyama</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shirato</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kawase</surname><given-names>M.</given-names></name><name name-style="western"><surname>Terada</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kawachi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fukushi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kamitani</surname><given-names>W.</given-names></name></person-group><article-title>Middle East respiratory syndrome coronavirus spike protein is not activated directly by cellular furin during viral entry into target cells</article-title><source>J. Virol.</source><year>2018</year><volume>92</volume><fpage>e00683-18</fpage><pub-id pub-id-type="doi">10.1128/JVI.00683-18</pub-id><pub-id pub-id-type="pmid">30021905</pub-id><pub-id pub-id-type="pmcid">PMC6146822</pub-id></element-citation></ref><ref id="B79-viruses-11-00060"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barlan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sarkar</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>K.</given-names></name><name name-style="western"><surname>McCray</surname><given-names>P.B.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Perlman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gallagher</surname><given-names>T.</given-names></name></person-group><article-title>Receptor variation and susceptibility to Middle East respiratory syndrome coronavirus infection</article-title><source>J. Virol.</source><year>2014</year><volume>88</volume><fpage>4953</fpage><lpage>4961</lpage><pub-id pub-id-type="doi">10.1128/JVI.00161-14</pub-id><pub-id pub-id-type="pmid">24554656</pub-id><pub-id pub-id-type="pmcid">PMC3993797</pub-id></element-citation></ref><ref id="B80-viruses-11-00060"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Doremalen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Miazgowicz</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Milne-Price</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bushmaker</surname><given-names>T.</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kinne</surname><given-names>J.</given-names></name><name name-style="western"><surname>McLellan</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Munster</surname><given-names>V.J.</given-names></name></person-group><article-title>Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4</article-title><source>J. Virol.</source><year>2014</year><volume>88</volume><fpage>9220</fpage><lpage>9232</lpage><pub-id pub-id-type="pmid">24899185</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.00676-14</pub-id><pub-id pub-id-type="pmcid">PMC4136254</pub-id></element-citation></ref><ref id="B81-viruses-11-00060"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Letko</surname><given-names>M.</given-names></name><name name-style="western"><surname>Miazgowicz</surname><given-names>K.</given-names></name><name name-style="western"><surname>McMinn</surname><given-names>R.</given-names></name><name name-style="western"><surname>Seifert</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Sola</surname><given-names>I.</given-names></name><name name-style="western"><surname>Enjuanes</surname><given-names>L.</given-names></name><name name-style="western"><surname>Carmody</surname><given-names>A.</given-names></name><name name-style="western"><surname>van Doremalen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Munster</surname><given-names>V.</given-names></name></person-group><article-title>Adaptive evolution of MERS-CoV to species variation in DPP4</article-title><source>Cell Rep.</source><year>2018</year><volume>24</volume><fpage>1730</fpage><lpage>1737</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.07.045</pub-id><pub-id pub-id-type="pmid">30110630</pub-id><pub-id pub-id-type="pmcid">PMC7104223</pub-id></element-citation></ref><ref id="B82-viruses-11-00060"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Au-Yeung</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Sze</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Shuai</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Middle East respiratory syndrome coronavirus and bat coronavirus HKU9 both can utilize GRP78 for attachment onto host cells</article-title><source>J. Biol. Chem.</source><year>2018</year><volume>293</volume><fpage>11709</fpage><lpage>11726</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA118.001897</pub-id><pub-id pub-id-type="pmid">29887526</pub-id><pub-id pub-id-type="pmcid">PMC6066311</pub-id></element-citation></ref><ref id="B83-viruses-11-00060"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hulswit</surname><given-names>R.J.G.</given-names></name><name name-style="western"><surname>Widjaja</surname><given-names>I.</given-names></name><name name-style="western"><surname>Raj</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>McBride</surname><given-names>R.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Widagdo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tortorici</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>van Dieren</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2017</year><volume>114</volume><fpage>E8508</fpage><lpage>E8517</lpage><pub-id pub-id-type="doi">10.1073/pnas.1712592114</pub-id><pub-id pub-id-type="pmid">28923942</pub-id><pub-id pub-id-type="pmcid">PMC5635925</pub-id></element-citation></ref><ref id="B84-viruses-11-00060"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>P.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4</article-title><source>Cell Res.</source><year>2013</year><volume>23</volume><fpage>986</fpage><lpage>993</lpage><pub-id pub-id-type="doi">10.1038/cr.2013.92</pub-id><pub-id pub-id-type="pmid">23835475</pub-id><pub-id pub-id-type="pmcid">PMC3731569</pub-id></element-citation></ref><ref id="B85-viruses-11-00060"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26</article-title><source>Nature</source><year>2013</year><volume>500</volume><fpage>227</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1038/nature12328</pub-id><pub-id pub-id-type="pmid">23831647</pub-id><pub-id pub-id-type="pmcid">PMC7095341</pub-id></element-citation></ref><ref id="B86-viruses-11-00060"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains</article-title><source>Nat. Commun.</source><year>2017</year><volume>8</volume><fpage>15092</fpage><pub-id pub-id-type="doi">10.1038/ncomms15092</pub-id><pub-id pub-id-type="pmid">28393837</pub-id><pub-id pub-id-type="pmcid">PMC5394239</pub-id></element-citation></ref><ref id="B87-viruses-11-00060"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pallesen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Corbett</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Wrapp</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kirchdoerfer</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Cottrell</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2017</year><volume>114</volume><fpage>E7348</fpage><lpage>E7357</lpage><pub-id pub-id-type="doi">10.1073/pnas.1707304114</pub-id><pub-id pub-id-type="pmid">28807998</pub-id><pub-id pub-id-type="pmcid">PMC5584442</pub-id></element-citation></ref><ref id="B88-viruses-11-00060"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W.</given-names></name></person-group><article-title>Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e112602</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0112602</pub-id><pub-id pub-id-type="pmid">25405618</pub-id><pub-id pub-id-type="pmcid">PMC4236105</pub-id></element-citation></ref><ref id="B89-viruses-11-00060"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Son</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Byun</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Sung</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Chaperna-mediated assembly of ferritin-based Middle East respiratory syndrome-coronavirus nanoparticles</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>1093</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.01093</pub-id><pub-id pub-id-type="pmid">29868035</pub-id><pub-id pub-id-type="pmcid">PMC5966535</pub-id></element-citation></ref><ref id="B90-viruses-11-00060"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice</article-title><source>Antiviral Res.</source><year>2017</year><volume>140</volume><fpage>55</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2016.12.019</pub-id><pub-id pub-id-type="pmid">28040513</pub-id><pub-id pub-id-type="pmcid">PMC7113847</pub-id></element-citation></ref><ref id="B91-viruses-11-00060"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G.F.</given-names></name><etal/></person-group><article-title>Recombinant receptor binding domain protein induces partial protective immunity in Rhesus Macaques against Middle East respiratory syndrome coronavirus challenge</article-title><source>EBioMedicine</source><year>2015</year><volume>2</volume><fpage>1438</fpage><lpage>1446</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2015.08.031</pub-id><pub-id pub-id-type="pmid">26629538</pub-id><pub-id pub-id-type="pmcid">PMC4634622</pub-id></element-citation></ref><ref id="B92-viruses-11-00060"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Channappanavar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Garron</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tasneem</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C.T.</given-names></name><etal/></person-group><article-title>Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus</article-title><source>Cell Mol. Immunol.</source><year>2016</year><volume>13</volume><fpage>180</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1038/cmi.2015.03</pub-id><pub-id pub-id-type="pmid">25640653</pub-id><pub-id pub-id-type="pmcid">PMC4786625</pub-id></element-citation></ref><ref id="B93-viruses-11-00060"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines</article-title><source>Nat. Commun.</source><year>2016</year><volume>7</volume><fpage>13473</fpage><pub-id pub-id-type="doi">10.1038/ncomms13473</pub-id><pub-id pub-id-type="pmid">27874853</pub-id><pub-id pub-id-type="pmcid">PMC5121417</pub-id></element-citation></ref><ref id="B94-viruses-11-00060"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><etal/></person-group><article-title>A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection</article-title><source>Virology</source><year>2016</year><volume>499</volume><fpage>375</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2016.10.005</pub-id><pub-id pub-id-type="pmid">27750111</pub-id><pub-id pub-id-type="pmcid">PMC5167628</pub-id></element-citation></ref><ref id="B95-viruses-11-00060"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name></person-group><article-title>Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>6170</fpage><lpage>6176</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.08.086</pub-id><pub-id pub-id-type="pmid">25240756</pub-id><pub-id pub-id-type="pmcid">PMC4194190</pub-id></element-citation></ref><ref id="B96-viruses-11-00060"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name></person-group><article-title>Receptor-binding domain-based subunit vaccines against MERS-CoV</article-title><source>Virus Res.</source><year>2015</year><volume>202</volume><fpage>151</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2014.11.013</pub-id><pub-id pub-id-type="pmid">25445336</pub-id><pub-id pub-id-type="pmcid">PMC4439384</pub-id></element-citation></ref><ref id="B97-viruses-11-00060"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name></person-group><article-title>Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus</article-title><source>Hum. Vaccin Immunother.</source><year>2015</year><volume>11</volume><fpage>1244</fpage><lpage>1250</lpage><pub-id pub-id-type="doi">10.1080/21645515.2015.1021527</pub-id><pub-id pub-id-type="pmid">25874632</pub-id><pub-id pub-id-type="pmcid">PMC4514392</pub-id></element-citation></ref><ref id="B98-viruses-11-00060"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name></person-group><article-title>Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection</article-title><source>Hum. Vaccin Immunother.</source><year>2017</year><volume>13</volume><fpage>1615</fpage><lpage>1624</lpage><pub-id pub-id-type="doi">10.1080/21645515.2017.1296994</pub-id><pub-id pub-id-type="pmid">28277821</pub-id><pub-id pub-id-type="pmcid">PMC5512770</pub-id></element-citation></ref><ref id="B99-viruses-11-00060"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nyon</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Seid</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Pollet</surname><given-names>J.</given-names></name><name name-style="western"><surname>Naceanceno</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Algaissi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Tai</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><fpage>1853</fpage><lpage>1862</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.02.065</pub-id><pub-id pub-id-type="pmid">29496347</pub-id><pub-id pub-id-type="pmcid">PMC5860679</pub-id></element-citation></ref><ref id="B100-viruses-11-00060"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fett</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name></person-group><article-title>Recombinant receptor-binding domains of multiple Middle East respiratory syndrome coronaviruses (MERS-CoVs) induce cross-neutralizing antibodies against divergent human and camel MERS-CoVs and antibody escape mutants</article-title><source>J. Virol.</source><year>2017</year><volume>91</volume><fpage>e01651-16</fpage><pub-id pub-id-type="doi">10.1128/JVI.01651-16</pub-id><pub-id pub-id-type="pmid">27795425</pub-id><pub-id pub-id-type="pmcid">PMC5165220</pub-id></element-citation></ref><ref id="B101-viruses-11-00060"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><fpage>2100</fpage><lpage>2108</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.02.004</pub-id><pub-id pub-id-type="pmid">24560617</pub-id><pub-id pub-id-type="pmcid">PMC4194189</pub-id></element-citation></ref><ref id="B102-viruses-11-00060"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chappell</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kanekiyo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>van Doremalen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on MERS-CoV Spike to avoid neutralization escape</article-title><source>J. Virol</source><year>2018</year><fpage>JVI.02002-17</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.02002-17</pub-id><pub-id pub-id-type="pmcid">PMC5923077</pub-id><pub-id pub-id-type="pmid">29514901</pub-id></element-citation></ref><ref id="B103-viruses-11-00060"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><etal/></person-group><article-title>A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein</article-title><source>Cell. Res.</source><year>2015</year><volume>25</volume><fpage>1237</fpage><lpage>1249</lpage><pub-id pub-id-type="doi">10.1038/cr.2015.113</pub-id><pub-id pub-id-type="pmid">26391698</pub-id><pub-id pub-id-type="pmcid">PMC4650419</pub-id></element-citation></ref><ref id="B104-viruses-11-00060"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pedotti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Simonelli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Agnihothram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fett</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fernandez-Rodriguez</surname><given-names>B.</given-names></name><name name-style="western"><surname>Foglierini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Agatic</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vanzetta</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2015</year><volume>112</volume><fpage>10473</fpage><lpage>10478</lpage><pub-id pub-id-type="doi">10.1073/pnas.1510199112</pub-id><pub-id pub-id-type="pmid">26216974</pub-id><pub-id pub-id-type="pmcid">PMC4547275</pub-id></element-citation></ref><ref id="B105-viruses-11-00060"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pascal</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Mujica</surname><given-names>A.O.</given-names></name><name name-style="western"><surname>Kamat</surname><given-names>V.</given-names></name><name name-style="western"><surname>Badithe</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fairhurst</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hunt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Strein</surname><given-names>J.</given-names></name><name name-style="western"><surname>Berrebi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sisk</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2015</year><volume>112</volume><fpage>8738</fpage><lpage>8743</lpage><pub-id pub-id-type="doi">10.1073/pnas.1510830112</pub-id><pub-id pub-id-type="pmid">26124093</pub-id><pub-id pub-id-type="pmcid">PMC4507189</pub-id></element-citation></ref><ref id="B106-viruses-11-00060"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ying</surname><given-names>T.</given-names></name><name name-style="western"><surname>Prabakaran</surname><given-names>P.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dimitrov</surname><given-names>D.S.</given-names></name><etal/></person-group><article-title>Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody</article-title><source>Nat. Commun.</source><year>2015</year><volume>6</volume><fpage>8223</fpage><pub-id pub-id-type="doi">10.1038/ncomms9223</pub-id><pub-id pub-id-type="pmid">26370782</pub-id><pub-id pub-id-type="pmcid">PMC4571279</pub-id></element-citation></ref><ref id="B107-viruses-11-00060"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name></person-group><article-title>Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection</article-title><source>Antiviral Res.</source><year>2016</year><volume>132</volume><fpage>141</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2016.06.003</pub-id><pub-id pub-id-type="pmid">27312105</pub-id><pub-id pub-id-type="pmcid">PMC5109928</pub-id></element-citation></ref><ref id="B108-viruses-11-00060"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C.T.</given-names></name><etal/></person-group><article-title>A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein</article-title><source>J. Virol.</source><year>2014</year><volume>88</volume><fpage>7045</fpage><lpage>7053</lpage><pub-id pub-id-type="doi">10.1128/JVI.00433-14</pub-id><pub-id pub-id-type="pmid">24719424</pub-id><pub-id pub-id-type="pmcid">PMC4054355</pub-id></element-citation></ref><ref id="B109-viruses-11-00060"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ying</surname><given-names>T.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ju</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Prabakaran</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Exceptionally potent neutralization of middle East respiratory syndrome coronavirus by human monoclonal antibodies</article-title><source>J. Virol.</source><year>2014</year><volume>88</volume><fpage>7796</fpage><lpage>7805</lpage><pub-id pub-id-type="doi">10.1128/JVI.00912-14</pub-id><pub-id pub-id-type="pmid">24789777</pub-id><pub-id pub-id-type="pmcid">PMC4097770</pub-id></element-citation></ref><ref id="B110-viruses-11-00060"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>Middle East respiratory syndrome: Current status and future prospects for vaccine development</article-title><source>Expert. Opin. Biol. Ther.</source><year>2015</year><volume>15</volume><fpage>1647</fpage><lpage>1651</lpage><pub-id pub-id-type="doi">10.1517/14712598.2015.1092518</pub-id><pub-id pub-id-type="pmid">26414077</pub-id><pub-id pub-id-type="pmcid">PMC4636333</pub-id></element-citation></ref><ref id="B111-viruses-11-00060"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Modjarrad</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lees</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yassine</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Kanekiyo</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Evaluation of candidate vaccine approaches for MERS-CoV</article-title><source>Nat. Commun.</source><year>2015</year><volume>6</volume><fpage>7712</fpage><pub-id pub-id-type="doi">10.1038/ncomms8712</pub-id><pub-id pub-id-type="pmid">26218507</pub-id><pub-id pub-id-type="pmcid">PMC4525294</pub-id></element-citation></ref><ref id="B112-viruses-11-00060"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W.</given-names></name></person-group><article-title>A novel human mAb (MERS-GD27) provides prophylactic and postexposure efficacy in MERS-CoV susceptible mice</article-title><source>Sci. China Life Sci.</source><year>2018</year><volume>61</volume><fpage>1280</fpage><lpage>1282</lpage><pub-id pub-id-type="doi">10.1007/s11427-018-9343-8</pub-id><pub-id pub-id-type="pmid">30091015</pub-id><pub-id pub-id-type="pmcid">PMC7089443</pub-id></element-citation></ref><ref id="B113-viruses-11-00060"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>P.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Ultrapotent human neutralizing antibody repertoires against Middle East respiratory syndrome coronavirus from a recovered patient</article-title><source>J. Infect Dis.</source><year>2018</year><volume>218</volume><fpage>1249</fpage><lpage>1260</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiy311</pub-id><pub-id pub-id-type="pmid">29846635</pub-id><pub-id pub-id-type="pmcid">PMC7107445</pub-id></element-citation></ref><ref id="B114-viruses-11-00060"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Human neutralizing monoclonal antibody inhibition of Middle East respiratory syndrome coronavirus replication in the common marmoset</article-title><source>J. Infect Dis.</source><year>2017</year><volume>215</volume><fpage>1807</fpage><lpage>1815</lpage><pub-id pub-id-type="doi">10.1093/infdis/jix209</pub-id><pub-id pub-id-type="pmid">28472421</pub-id><pub-id pub-id-type="pmcid">PMC7107363</pub-id></element-citation></ref><ref id="B115-viruses-11-00060"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Structural definition of a unique neutralization epitope on the receptor-binding domain of MERS-CoV spike glycoprotein</article-title><source>Cell Rep.</source><year>2018</year><volume>24</volume><fpage>441</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.06.041</pub-id><pub-id pub-id-type="pmid">29996104</pub-id><pub-id pub-id-type="pmcid">PMC7104183</pub-id></element-citation></ref><ref id="B116-viruses-11-00060"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raj</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Okba</surname><given-names>N.M.A.</given-names></name><name name-style="western"><surname>Gutierrez-Alvarez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Drabek</surname><given-names>D.</given-names></name><name name-style="western"><surname>van Dieren</surname><given-names>B.</given-names></name><name name-style="western"><surname>Widagdo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lamers</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Widjaja</surname><given-names>I.</given-names></name><name name-style="western"><surname>Fernandez-Delgado</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sola</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection</article-title><source>Sci. Adv.</source><year>2018</year><volume>4</volume><fpage>eaas9667</fpage><pub-id pub-id-type="doi">10.1126/sciadv.aas9667</pub-id><pub-id pub-id-type="pmid">30101189</pub-id><pub-id pub-id-type="pmcid">PMC6082650</pub-id></element-citation></ref><ref id="B117-viruses-11-00060"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>He</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>A novel nanobody targeting Middle East respiratory syndrome coronavirus (MERS-CoV) receptor-binding domain has potent cross-neutralizing activity and protective efficacy against MERS-CoV</article-title><source>J. Virol</source><year>2018</year><volume>92</volume><fpage>e00837-18</fpage><pub-id pub-id-type="doi">10.1128/JVI.00837-18</pub-id><pub-id pub-id-type="pmid">29950421</pub-id><pub-id pub-id-type="pmcid">PMC6146697</pub-id></element-citation></ref><ref id="B118-viruses-11-00060"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Structural basis for the neutralization of MERS-CoV by a human monoclonal antibody MERS-27</article-title><source>Sci Rep.</source><year>2015</year><volume>5</volume><fpage>13133</fpage><pub-id pub-id-type="doi">10.1038/srep13133</pub-id><pub-id pub-id-type="pmid">26281793</pub-id><pub-id pub-id-type="pmcid">PMC4539535</pub-id></element-citation></ref><ref id="B119-viruses-11-00060"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilken</surname><given-names>L.</given-names></name><name name-style="western"><surname>McPherson</surname><given-names>A.</given-names></name></person-group><article-title>Application of camelid heavy-chain variable domains (VHHs) in prevention and treatment of bacterial and viral infections</article-title><source>Int. Rev. Immunol.</source><year>2018</year><volume>37</volume><fpage>69</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1080/08830185.2017.1397657</pub-id><pub-id pub-id-type="pmid">29182399</pub-id></element-citation></ref><ref id="B120-viruses-11-00060"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Heeke</surname><given-names>G.</given-names></name><name name-style="western"><surname>Allosery</surname><given-names>K.</given-names></name><name name-style="western"><surname>De Brabandere</surname><given-names>V.</given-names></name><name name-style="western"><surname>De Smedt</surname><given-names>T.</given-names></name><name name-style="western"><surname>Detalle</surname><given-names>L.</given-names></name><name name-style="western"><surname>de Fougerolles</surname><given-names>A.</given-names></name></person-group><article-title>Nanobodies(R) as inhaled biotherapeutics for lung diseases</article-title><source>Pharmacol. Ther.</source><year>2017</year><volume>169</volume><fpage>47</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">27373507</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pharmthera.2016.06.012</pub-id></element-citation></ref><ref id="B121-viruses-11-00060"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Detalle</surname><given-names>L.</given-names></name><name name-style="western"><surname>Stohr</surname><given-names>T.</given-names></name><name name-style="western"><surname>Palomo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Piedra</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Mas</surname><given-names>V.</given-names></name><name name-style="western"><surname>Millar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Power</surname><given-names>U.F.</given-names></name><name name-style="western"><surname>Stortelers</surname><given-names>C.</given-names></name><name name-style="western"><surname>Allosery</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection</article-title><source>Antimicrob. Agents Chemother.</source><year>2015</year><volume>60</volume><fpage>6</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1128/AAC.01802-15</pub-id><pub-id pub-id-type="pmid">26438495</pub-id><pub-id pub-id-type="pmcid">PMC4704182</pub-id></element-citation></ref><ref id="B122-viruses-11-00060"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steeland</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vandenbroucke</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Libert</surname><given-names>C.</given-names></name></person-group><article-title>Nanobodies as therapeutics: Big opportunities for small antibodies</article-title><source>Drug Discov. Today</source><year>2016</year><volume>21</volume><fpage>1076</fpage><lpage>1113</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2016.04.003</pub-id><pub-id pub-id-type="pmid">27080147</pub-id></element-citation></ref><ref id="B123-viruses-11-00060"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muyldermans</surname><given-names>S.</given-names></name></person-group><article-title>Nanobodies: Natural single-domain antibodies</article-title><source>Annu. Rev. Biochem.</source><year>2013</year><volume>82</volume><fpage>775</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-063011-092449</pub-id><pub-id pub-id-type="pmid">23495938</pub-id></element-citation></ref><ref id="B124-viruses-11-00060"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>Vaccines for the prevention against the threat of MERS-CoV</article-title><source>Expert Rev. Vaccines</source><year>2016</year><volume>15</volume><fpage>1123</fpage><lpage>1134</lpage><pub-id pub-id-type="doi">10.1586/14760584.2016.1167603</pub-id><pub-id pub-id-type="pmid">26985862</pub-id><pub-id pub-id-type="pmcid">PMC5097835</pub-id></element-citation></ref><ref id="B125-viruses-11-00060"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>X.</given-names></name></person-group><article-title>Evolutionary dynamics of MERS-CoV: Potential recombination, positive selection and transmission</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>25049</fpage><pub-id pub-id-type="doi">10.1038/srep25049</pub-id><pub-id pub-id-type="pmid">27142087</pub-id><pub-id pub-id-type="pmcid">PMC4855236</pub-id></element-citation></ref><ref id="B126-viruses-11-00060"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cheon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Min</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Sohn</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Cha</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Han</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Ha</surname><given-names>N.Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Spread of mutant Middle East respiratory syndrome coronavirus with reduced affinity to human CD26 during the South Korean outbreak</article-title><source>MBio</source><year>2016</year><volume>7</volume><fpage>e00019</fpage><pub-id pub-id-type="doi">10.1128/mBio.00019-16</pub-id><pub-id pub-id-type="pmid">26933050</pub-id><pub-id pub-id-type="pmcid">PMC4810480</pub-id></element-citation></ref><ref id="B127-viruses-11-00060"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kleine-Weber</surname><given-names>H.</given-names></name><name name-style="western"><surname>Elzayat</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Drosten</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pohlmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>M.</given-names></name></person-group><article-title>Mutations in the spike protein of Middle East respiratory syndrome coronavirus transmitted in Korea increase resistance to antibody-mediated neutralization</article-title><source>J. Virol.</source><year>2019</year><volume>93</volume><fpage>e01381-18</fpage><pub-id pub-id-type="doi">10.1128/JVI.01381-18</pub-id><pub-id pub-id-type="pmid">30404801</pub-id><pub-id pub-id-type="pmcid">PMC6321919</pub-id></element-citation></ref><ref id="B128-viruses-11-00060"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hua</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>Combining a fusion inhibitory peptide targeting the MERS-CoV S2 protein HR1 domain and a neutralizing antibody specific for the S1 protein receptor-binding domain (RBD) showed potent synergism against pseudotyped MERS-CoV with or without mutations in RBD</article-title><source>Viruses</source><year>2019</year><volume>11</volume><elocation-id>31</elocation-id><pub-id pub-id-type="doi">10.3390/v11010031</pub-id><pub-id pub-id-type="pmcid">PMC6356712</pub-id><pub-id pub-id-type="pmid">30621343</pub-id></element-citation></ref><ref id="B129-viruses-11-00060"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galasiti Kankanamalage</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Damalanka</surname><given-names>V.C.</given-names></name><name name-style="western"><surname>Rathnayake</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Fehr</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Mehzabeen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Battaile</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Lovell</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lushington</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element</article-title><source>Eur. J. Med. Chem</source><year>2018</year><volume>150</volume><fpage>334</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2018.03.004</pub-id><pub-id pub-id-type="pmid">29544147</pub-id><pub-id pub-id-type="pmcid">PMC5891363</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="viruses-11-00060-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Schematic structures of MERS-CoV S protein. (<bold>A</bold>) MERS-CoV genomic structure, with the untranslated region (UTR), open reading frame regions ORF1a and ORF1b, spike (S), envelope (E), membrane (M), and nucleocapsid (N) genes. (<bold>B</bold>) Schematic structure of the MERS-CoV virion and its major structural proteins. (<bold>C</bold>) Schematic structure of the MERS-CoV S protein and its functional domains, including the N-terminal domain (NTD), receptor-binding domain (RBD), receptor-binding motif (RBM), fusion peptide (FP), heptad repeat region 1 and 2 (HR1 and HR2), transmembrane region (TM), and cytoplasmic tail (CP). aa, amino acid; MERS-CoV, Middle East respiratory syndrome coronavirus; nt, nucleotide.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="viruses-11-00060-g001.jpg"/></fig><fig id="viruses-11-00060-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Structural basis of MERS-CoV S-protein RBD&#8211;DPP4 interaction. Structural data for the complex of MERS-CoV S-protein RBD bound to DPP4 are from the protein data bank (PDB) (ID: 4KR0). The MERS-CoV RBD core is colored in blue, the RBM is colored in red, and DPP4 is colored in green. The RBM residues directly involved in DPP4 binding are shown as sticks. DPP4, dipeptidyl peptidase 4; RBD, receptor-binding domain; RBM, receptor-binding motif; S, spike protein.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="viruses-11-00060-g002.jpg"/></fig><fig id="viruses-11-00060-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Models of the MERS-CoV S-protein trimer bound to DPP4. The models were generated by superimposing the MERS-CoV RBD in the structure of the MERS-CoV S-protein RBD&#8211;DPP4 complex (PDB ID: 4KR0) onto the RBDs in the structures of MERS-CoV S-protein trimers with (<bold>A</bold>) one RBD (PDB ID: 5X5F), (<bold>B</bold>) two RBDs (PDB ID: 5X5C), or (<bold>C</bold>) three RBDs (PDB ID: 5X59) in the &#8220;standing&#8221; conformation. The MERS-CoV S-protein trimers are colored in gray, with three RBDs colored in red, blue, and green. Three DPP4 dimers are colored in plum, orange, and yellow. DPP4, dipeptidyl peptidase 4; PDB, protein data bank; RBD, receptor-binding domain; S, spike protein.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="viruses-11-00060-g003.jpg"/></fig><fig id="viruses-11-00060-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Structural basis for MERS-CoV RBD recognition by neutralizing mAbs. (<bold>A</bold>) Crystal structure of MERS-CoV RBD complexed with MCA1 mAb (PDB ID: 5GMQ). (<bold>B</bold>) Crystal structure of the MERS-CoV RBD complexed with CDC2-C2 mAb (PDB ID: 6C6Z). (<bold>C</bold>) Crystal structure of the MERS-CoV RBD complexed with JC57-14 mAb (PDB ID: 6C6Y). (<bold>D</bold>) Crystal structure of MERS-CoV RBD complexed with MERS-4 mAb (PDB ID: 5ZXV). The MERS-CoV RBD core is colored in blue, the RBM is colored in red, and the heavy chains and light chains of each mAb are colored in green and yellow, respectively. The DPP4-binding residues that are blocked by each mAb are shown as sticks. mAb, monoclonal antibody; MERS-CoV, Middle East respiratory syndrome coronavirus; PDB, protein data bank; RBD, receptor-binding domain; RBM, receptor-binding motif.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="viruses-11-00060-g004.jpg"/></fig><table-wrap id="viruses-11-00060-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">viruses-11-00060-t001_Table 1</object-id><label>Table 1</label><caption><p>Vaccines based on MERS-CoV RBD. Live MERS-CoV strains used for neutralization and challenge experiments, as well as vaccine-induced neutralizing-antibody titers, are described in parentheses.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Name</th><th valign="top" align="left" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Functionality and Antigenicity</th><th valign="top" align="left" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Immunogenicity in Induction of Antibody Response</th><th valign="top" align="left" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Immunogenicity in Induction of Cellular Immune Response</th><th valign="top" align="left" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Protective Immunity</th><th valign="top" align="left" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref. </th></tr></thead><tbody><tr><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">RBD-[SSG]-FR and RBD-FR nanoparticles</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Bind to DPP4 receptor; antisera block RBD-hDPP4 binding</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Induce MERS-CoV RBD-specific antibodies (IgG, IgG1, IgG2a, IgG2b, IgA) in mice</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Elicit MERS-CoV RBD-specific T-cell responses (IFN-&#947;, TNF-&#945;) in mouse splenocytes</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B89-viruses-11-00060" ref-type="bibr">89</xref>]</td></tr><tr><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">sVLP <break/>(spherical virus-like particle)</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Induces MERS-CoV RBD-specific antibodies (IgG) in mice, neutralizing pseudotyped MERS-CoV (1:320)</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Elicits MERS-CoV RBD-specific cellular immune response (IFN-&#947;, IL-2, IL-4) in mouse splenocytes </td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B90-viruses-11-00060" ref-type="bibr">90</xref>]</td></tr><tr><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">rRBD (recombinant RBD)</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Induces MERS-CoV RBD-specific antibodies (IgG, IgG1, IgG2a) in mice or NHPs, neutralizing pseudotyped (1:800 to 1:1,600) and live (EMC2012: 1:269 to 1:363) MERS-CoV</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Elicits MERS-CoV RBD-specific cellular immune response (TNF-&#945;, IFN-&#947;, IL-2, IL-4, IL-6) in mouse splenocytes or monkey PBMCs</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Partially protects NHPs from MERS-CoV (EMC2012: 6.5 &#215; 10<sup>7</sup> TCID<sub>50</sub>) infection with alleviated pneumonia and decreased viral load</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B88-viruses-11-00060" ref-type="bibr">88</xref>,<xref rid="B91-viruses-11-00060" ref-type="bibr">91</xref>]</td></tr><tr><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">RBD<break/>(S377-588)-Fc</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Binds strongly to soluble and cell-associated hDPP4 or cDPP4 receptors and MERS-CoV RBD-specific neutralizing mAbs (Mersmab1, m336, m337, m338)</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Induces MERS-CoV S1-specific antibodies (IgG, IgG1, IgG2a) in mice and rabbits, cross-neutralizing 17 pseudotyped (&gt;1:10<sup>4</sup>), 2 live (EMC2012, London1-2012: &#8805;1:10<sup>3</sup>) MERS-CoV, and 5 mAb escape mutants (&gt;1:10<sup>4</sup>)</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Elicits MERS-CoV S1-specific cellular immune responses (IFN-&#947;, IL-2) in mouse splenocytes</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Protects Ad5/hDPP4-transduced BALB/c mice and hDPP4-Tg mice (67% survival rate) from challenge by MERS-CoV (EMC2012: 10<sup>5</sup> PFU for BALB/c; 10<sup>3&#8211;</sup>10<sup>4</sup> TCID<sub>50</sub> for Tg), without toxicity or immune enhancement</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B92-viruses-11-00060" ref-type="bibr">92</xref>,<xref rid="B95-viruses-11-00060" ref-type="bibr">95</xref>,<xref rid="B96-viruses-11-00060" ref-type="bibr">96</xref>,<xref rid="B97-viruses-11-00060" ref-type="bibr">97</xref>,<xref rid="B98-viruses-11-00060" ref-type="bibr">98</xref>,<xref rid="B99-viruses-11-00060" ref-type="bibr">99</xref>]</td></tr><tr><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">2012-RBD<break/>2013-RBD<break/>2014-RBD<break/>2015-RBD<break/>Camel-RBD</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Bind strongly to hDPP4 and cDPP4 receptors and MERS-CoV RBD-specific mAbs (Mersmab1, m336, m337, m338) with high affinity</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Induce MERS-CoV S1-specific antibodies (IgG, IgG1, IgG2a) in mice, potently cross-neutralizing 17 pseudotyped (&#8805;1:10<sup>4</sup>), 2 live (EMC2012, London1-2012: &gt;1:10<sup>2</sup>) MERS-CoV, and 5 mAb escape mutants (&#8805;1:10<sup>4</sup>)</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B100-viruses-11-00060" ref-type="bibr">100</xref>]</td></tr><tr><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">RBD-Fd</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Binds strongly to soluble and cell-associated hDPP4 receptors and MERS-CoV RBD-specific mAbs (Mersmab1, m336, m337, m338)</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Induces robust and long-term MERS-CoV S1-specific antibodies (IgG, IgG1, IgG2a) in mice, neutralizing at least 9 pseudotyped (&gt;1:10<sup>4</sup>) and live (EMC2012: &gt;1:10<sup>3</sup>) MERS-CoV</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Protects hDPP4-Tg mice (83% survival rate) from lethal MERS-CoV (EMC2012: 10<sup>4</sup> TCID<sub>50</sub>) challenge </td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B94-viruses-11-00060" ref-type="bibr">94</xref>]</td></tr><tr><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">RBD (T579N)</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Binds strongly to soluble and cell-associated hDPP4 receptors and MERS-CoV RBD-specific mAbs (hHS-1, m336, m337, m338)</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Induces highly potent neutralizing antibodies in mice against live MERS-CoV (EMC2012: &gt;1:3 &#215; 10<sup>3</sup>)</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Significantly enhances efficacy in fully protecting hDPP4-Tg mice (100% survival rate) from lethal MERS-CoV (EMC2012: 10<sup>4</sup> TCID<sub>50</sub>) challenge</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B93-viruses-11-00060" ref-type="bibr">93</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Note: Ad5, adenovirus 5; DPP4, dipeptidyl peptidase 4; cDPP4, camel DPP4; hDPP4, human DPP4; hDPP4-Tg, hDPP4-transgenic; Fd, foldon; FR, ferritin; mAb, monoclonal antibody; N/A, not available or not applicable; NHP, non-human primate; PBMCs, peripheral blood mononuclear cells; PFU, plaque-forming unit; RBD, receptor-binding domain; S, spike; TCID<sub>50</sub>, median tissue-culture infectious dose.</p></fn></table-wrap-foot></table-wrap><table-wrap id="viruses-11-00060-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">viruses-11-00060-t002_Table 2</object-id><label>Table 2</label><caption><p>Therapeutic antibodies targeting MERS-CoV RBD. Live MERS-CoV strains used for neutralization and challenge experiments are indicated in parentheses.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" align="left" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Name</th><th valign="middle" align="left" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Source</th><th valign="middle" align="left" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Binding MERS-CoV RBD</th><th valign="middle" align="left" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Structure Available</th><th valign="middle" align="left" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">In vitro Anti-MERS-CoV Activity</th><th valign="middle" align="left" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">In vivo Protection</th><th valign="middle" align="left" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">MERS-GD27 MERS-GD33 mAbs</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Human</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">K</italic><sub>d</sub>: 0.775 nM (for MERS-GD27) and 0.575 nM (for MERS-GD33). Recognize RBD residues L506, D510, E513, W535, E536, D539, E540, W553 (for MERS-GD27), R511, and A556 (for MERS-GD33)</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes, crystal structure for the Fab&#8211;RBD complex</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub>: 0.001 &#181;g/mL against pseudotyped MERS-CoV; 0.001 &#181;g/mL against live MERS-CoV; both mAbs have synergistic effect against pseudotyped MERS-CoV with reduced IC<sub>50</sub> by 0.499-fold (for MERS-GD27) or 6.05-fold (for MERS-GD33) vs individual mAbs</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">MERS-GD27 prophylactically and therapeutically protects hDPP4-Tg mice against MERS-CoV (EMC2012: 3 LD<sub>50</sub>) with 60% and 40% survival rates, respectively</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B112-viruses-11-00060" ref-type="bibr">112</xref>,<xref rid="B113-viruses-11-00060" ref-type="bibr">113</xref>]</td></tr><tr><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">MCA1 <break/>mAb</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Human</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Recognizes RBD residues D510, W535, E536, D539, Y540, R542, and Q544</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes, crystal structure for the Fab&#8211;RBD complex</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub>: 0.39 &#181;g/mL against live MERS-CoV (EMC2012) </td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Prophylactically and therapeutically (5&#8211;20 mg/kg) inhibits MERS-CoV (EMC2012: 5 &#215; 10<sup>6</sup> TCID<sub>50</sub>) replication in common marmosets, improving clinical outcomes and reducing lung disease and viral replication</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B114-viruses-11-00060" ref-type="bibr">114</xref>]</td></tr><tr><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">JC57-14 <break/>mAb</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Macaque</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Recognizes RBD residues W535, E536, D539, Y540, and R542</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes, crystal structure for the Fab&#8211;RBD complex</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub>: 0.0084 &#181;g/mL against pseudotyped MERS-CoV and 0.07 &#181;g/mL against live MERS-CoV (EMC2012), cross-neutralizing 8 pseudotyped MERS-CoVs</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B102-viruses-11-00060" ref-type="bibr">102</xref>]</td></tr><tr><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">CDC2-C2 mAb</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Human</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Recognizes RBD residues F506, D509, W535, E536, D539, Y540, and R542</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes, crystal structure for the Fab&#8211;RBD complex</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub>: 0.0057 &#181;g/mL against pseudotyped MERS-CoV and 0.058 &#181;g/mL against live MERS-CoV (EMC2012), cross-neutralizing 10 pseudotyped MERS-CoVs</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Prophylactically (20 mg/kg) protects hDPP4-Tg mice against MERS-CoV (EMC2012: 10<sup>6</sup> TCID<sub>50</sub>) in lungs with 100% survival rate</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B102-viruses-11-00060" ref-type="bibr">102</xref>]</td></tr><tr><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">MERS-4 <break/>mAb</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Human</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Recognizes RBD residues L507, L545, S546, P547, G549; binds RBD from outside of the RBD DPP4-binding interface</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes, crystal structure for the Fab&#8211;RBD complex</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Has synergistic neutralization effect with MERS-27, m336, and 5F9 mAbs against pseudotyped MERS-CoV, with the reduction of IC<sub>50</sub> by 2.6-fold (for MERS-4 + m336) and 15.21-fold (for MERS-4 + 5F9)</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B115-viruses-11-00060" ref-type="bibr">115</xref>]</td></tr><tr><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">VHH-83<break/>HCAb-83 <break/>VHHs</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Dromedary</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">K</italic><sub>d</sub>: 0.1 nM (for VHH-83) and 2.5 pM (for HCAb-83). Recognizes RBD residue D539</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT<sub>50</sub>: 0.0012&#8211;0.0014 &#181;g/mL against live MERS-CoV (EMC2012)</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">HCAb-83 (200 &#181;g) prophylactically protects hDPP4-Tg mice (K18) against MERS-CoV (EMC2012: 10<sup>5</sup> PFU) in lungs with 100% survival rate</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B116-viruses-11-00060" ref-type="bibr">116</xref>]</td></tr><tr><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">NbMS10<break/>NbMS10-Fc <break/>VHHs</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">Llama</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">K</italic><sub>d</sub>: 0.87 nM (for NbMS10) and 0.35 nM (for NbMS10-Fc). Recognize RBD residue D539</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">N/A</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">IC<sub>50</sub>: 0.003&#8211;0.979 &#181;g/ml (for NbMS10) and 0.003&#8211;0.067 &#181;g/ml (for NbMS10-Fc) in cross-neutralizing &#8805;11 pseudotyped MERS-CoVs</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">NbMS10-Fc (10 mg/kg) prophylactically and therapeutically protects hDPP4-Tg mice against MERS-CoV (EMC2012, 10<sup>5.3</sup> TCID<sub>50</sub>) with 100% survival rate</td><td valign="top" align="left" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B117-viruses-11-00060" ref-type="bibr">117</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Note: DPP4, dipeptidyl peptidase 4; Fab, antigen-binding fragment; hDPP4-Tg, human DPP4-transgenic; IC<sub>50</sub>, half-maximal inhibitory concentration; <italic toggle="yes">K</italic><sub>d</sub>: antibody binding affinity; LD<sub>50</sub>, 50% lethal dose; N/A, not available or not applicable; PRNT<sub>50</sub>, 50% plaque-reduction neutralization titer; RBD, receptor-binding domain; TCID<sub>50</sub>, median tissue-culture infectious dose; VHH, single-domain antibody fragment.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>